Document:

QuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.1  

CONFIDENTIAL MATERIAL OMITTED AND FILED SEPARATELY WITH

THE SECURITIES AND EXCHANGE COMMISSION

ASTERISKS DENOTE SUCH OMISSIONS  

 
  LOAN AND SECURITY AGREEMENT    
  

        This LOAN AND SECURITY AGREEMENT (this "Agreement") dated as of March 27, 2002, between  SILICON VALLEY
BANK, a California chartered bank, with its principal place of business at 3003 Tasman Drive, Santa Clara, California 95054 and with a
loan production office located at One Newton Executive Park, Suite 200, 2221 Washington Street, Newton, Massachusetts 02462, doing business under the name "Silicon Valley East" ("Bank") and  GENZYME TRANSGENICS
CORPORATION, a Massachusetts corporation ("Borrower"), provides the terms on which Bank shall lend to Borrower and Borrower shall
repay Bank. The parties agree as follows: 

        1    ACCOUNTING AND OTHER TERMS    

        Accounting
terms not defined in this Agreement shall be construed following GAAP. Calculations and determinations must be made following GAAP. The term "financial statements" includes
the notes and schedules. The terms "including" and "includes" always mean "including (or includes) without limitation," in this or any Loan Document. Capitalized terms in this Agreement shall have the
meanings set forth in Section 13. 

        2    LOAN AND TERMS OF PAYMENT    

        2.1    Promise to Pay.    Borrower hereby unconditionally promises to pay Bank the unpaid principal amount of all
Credit Extensions and interest on the unpaid principal amount of the Credit Extensions as and when due in accordance with this Agreement. 

        2.1.1    Revolving Advances.    

                (a)    Availability.    Bank shall make Advances not exceeding (i) the Committed Revolving Line minus
(ii) the amount of all outstanding Letters of Credit (including drawn but unreimbursed Letters of Credit), minus (iii) the unused amount of the FX Reserve, and minus (iv) the
aggregate outstanding Advances hereunder. Amounts borrowed under this Section may be repaid and reborrowed during the term of this Agreement. 

                (b)    Borrowing Procedure.    To obtain an Advance, Borrower must notify Bank by facsimile or telephone by
3:00 p.m. Eastern time on the Business Day the Advance is to be made. If such notification is by telephone, Borrower must promptly confirm the notification by delivering to Bank a completed
Payment/Advance Form in the form attached as Exhibit B. Bank shall credit Advances to Borrower's deposit account. Bank may make Advances under
this Agreement based on instructions from a Responsible Officer or his or her designee or without instructions if the Advances are necessary to meet Obligations which have become due. Bank may rely on
any telephone notice given by a person whom Bank believes is a Responsible Officer or designee. Borrower shall indemnify Bank for any loss Bank suffers due to such reliance. 

                (c)    Termination; Repayment.    The Committed Revolving Line terminates on the Revolving Maturity Date, when the
principal amount of all Advances and the unpaid interest thereon, shall be immediately due and payable. 

                (d)    Interest.    Interest is payable on the Payment Date of each month. 

1

 

Letters of Credit.  

                (e)  Bank
shall issue or have issued Letters of Credit for Borrower's account not exceeding (i) the Committed Revolving Line, minus (ii) the outstanding
principal balance of any Advances, minus (iii) the amount of all Letters of Credit (including drawn but unreimbursed Letters of Credit), plus an amount equal to any Letter of Credit Reserves,
and minus (iv) the unused amount of the FX Reserve. The face amount of outstanding Letters of Credit (including drawn but unreimbursed Letters of Credit and any Letter of Credit Reserve) may
not exceed One Million Dollars ($1,000,000.00). Each Letter of Credit shall have an expiry date no later than 180 days after the Revolving Maturity Date provided Borrower's Letter of Credit
reimbursement obligation shall be secured by cash on terms acceptable to Bank on and after (i) the Revolving Maturity Date if the term of this Agreement is not extended by Bank, or
(ii) the occurrence of an Event of Default hereunder. All Letters of Credit shall be, in form and substance, acceptable to Bank in its sole discretion and shall be subject to the terms and
conditions of Bank's form of standard Application and Letter of Credit Agreement. Borrower agrees to execute any further documentation in connection with the Letters of Credit as Bank may reasonably
request. 

                (f)    The
obligation of Borrower to immediately reimburse Bank for drawings made under Letters of Credit shall be absolute, unconditional and irrevocable, and shall be
performed strictly in accordance with the terms of this Agreement and such Letters of Credit, under all circumstances whatsoever. Borrower shall indemnify, defend, protect, and hold Bank harmless from
any loss, cost, expense or liability, including, without limitation, reasonable attorneys' fees, arising out of or in connection with any Letters of Credit. 

                (g)  Borrower
may request that Bank issue a Letter of Credit payable in a currency other than United States Dollars. If a demand for payment is made under any such Letter of
Credit, Bank shall treat such demand as an Advance to Borrower of the equivalent of the amount thereof (plus cable charges) in United States currency at the then prevailing rate of exchange in San
Francisco, California, for sales of that other currency for cable transfer to the country of which it is the currency. 

                (h)  Upon
the issuance of any letter of credit payable in a currency other than United States Dollars, Bank shall create a reserve (the "Letter of Credit Reserve") under the
Committed Revolving Line for letters of credit against fluctuations in currency exchange rates, in an amount equal to ten percent (10%) of the face amount of such letter of credit. The amount of such
reserve may be amended by Bank from time to time to account for fluctuations in the exchange rate. The availability of funds under the Committed Revolving Line shall be reduced by the amount of such
reserve for so long as such letter of credit remains outstanding. 

Foreign Exchange Sublimit.  

        If there is availability under the Committed Revolving Line, then Borrower may enter in foreign exchange forward contracts with the Bank under which Borrower
commits to purchase from or sell to Bank a set amount of foreign currency more than one business day after the contract date (the "FX Forward Contract"). Bank shall subtract 10% of the nominal amount
of each outstanding FX Forward Contract from the foreign exchange sublimit which is a maximum of One Million Dollars ($1,000,000.00) (the "FX Reserve"). The total of the nominal amount of all FX
Forward Contracts at
any one time may not exceed 10 times the amount of the FX Reserve. Bank may terminate the FX Forward Contracts if an Event of Default occurs. 

Equipment Advances.  

                (i)    Availability.    Through March 27, 2003 [twelve months from the
Closing Date] (the "Equipment Availability End Date"), Bank shall make advances ("Equipment Advance" and, collectively, "Equipment Advances") not exceeding the
Committed Equipment Line. The Equipment Advances may only be used to finance Eligible Equipment purchased after January 1, 2002 and no 

2

 

Equipment Advances may exceed 100% of the equipment invoice excluding taxes, shipping, warranty charges, freight discounts and installation expense relating to such Equipment, unless such costs
constitute Other Equipment. Equipment Advances when repaid may not be reborrowed. 

                (j)    Interest Rate.    Interest accrues from the date of each Equipment Advance at the rate in
Section 2.2(a) and is payable monthly. 

                (k)    Repayment.    Equipment Advances outstanding on the Equipment Availability End Date are payable in
(a) 60 consecutive equal monthly installments of principal (based upon an amortization schedule of 120 months), plus, (b) monthly payments of accrued interest, on the Payment Date
occurring in each month commencing with the first such date following the Equipment Availability End Date and ending on March 27, 2008 (the "Equipment Maturity Date"), when the outstanding
principal balance of all Equipment Advances, and the unpaid interest thereon, shall be immediately due and payable. 

                (l)    To
obtain an Equipment Advance, Borrower must notify Bank (the notice is irrevocable) by facsimile no later than 3:00 p.m. Eastern time one (1) Business
Day before the day on which the Equipment Advance is to be made. The notice in the form of Exhibit B (Payment/Advance Form) must be signed by a
Responsible Officer or designee and include a copy of the invoice for the Equipment being financed. 

Term Loan.  

                (m)  Bank
shall advance, on behalf of Borrower, an amount equal to the Term Loan, on the Closing Date. The proceeds of the Term Loan shall be used: (i) to reimburse
Borrower for the Fleet Bank Payoff Amount, to refinance certain existing indebtedness with Fleet Bank, up to a maximum amount of Five Million Five Hundred Thousand Dollars ($5,500,000.00); and
(ii) for the refinance of Eligible Equipment purchased between March 1, 2001 and December 31, 2001 (the "Term Equipment Amount"). 

                (n)  The
Fleet Payoff Amount shall be advanced by Bank on behalf of the Borrower, subject to receipt by the Bank of a confirmation of payoff letter from Fleet Bank in form
and substance acceptable to the Bank. 

                (o)  For
the Term Equipment Amount, Borrower shall deliver an invoice or invoices for the Eligible Equipment to be refinanced on the Closing Date. 

                (p)  Borrower
shall repay the Term Loan in (a) 60 equal installments of principal, plus (b) monthly payments of interest (the "Term Loan Payment"), beginning
on the first day of the month following the Closing Date. Borrower's final payment under the Term Loan shall be payable on the sixty (60) month anniversary of the Closing Date and shall include
all outstanding principal and accrued interest. 

                (q)  The
Term Loan shall accrue interest at the rate specified in 2.2(a). 

        2.1.6    Undisbursed Credit Extensions.    The Bank's obligation to lend the undisbursed portion of the Credit
Extensions shall terminate if there has been a material adverse change in the general affairs, management, results of operation, condition (financial or otherwise) or the prospects of repayment of
Borrower, whether or not arising from transactions in the ordinary course of business, or there has been any material adverse deviation by Borrower from the most recent business plan of Borrower
presented to and accepted by Bank prior to the execution of this Agreement. 

        2.2    Interest Rate; Payments.    

                (a)    Interest Rate.    The principal amounts outstanding under the Committed Revolving Line, Committed Equipment
Line and the Term Loan shall accrue interest at a per annum rate equal to the 

3

 

Bank's Prime Rate. After the occurrence of an Event of Default, Obligations shall bear interest at five percent (5.0%) above the rate effective immediately before the Event of Default. The applicable
interest rate hereunder shall increase or decrease when the Prime Rate changes. Interest is computed on the basis of a 360 day year for the actual number of days elapsed. 

                (b)    Payments.    Interest is payable on the Payment Date of each month. Bank may debit any of Borrower's deposit
accounts including Account Number                        for principal and interest payments or any amounts Borrower owes Bank.
Bank shall promptly notify Borrower when it debits Borrower's accounts. These
debits are not a set-off. Payments received after 12:00 noon Eastern time are considered received at the opening of business on the next Business Day. When a payment is due on a day that
is not a Business Day, the payment is due the next Business Day and additional fees or interest, as applicable, shall continue to accrue. 

        2.3    Fees.    Borrower shall pay to Bank: 

                (a)    Facility Fee.    A fully earned, non-refundable facility fee of Two Thousand Five Hundred Dollars
($2,500.00) due on the Closing Date; and 

                (b)    Bank Expenses.    All Bank Expenses (including reasonable attorneys' fees and expenses incurred through and
after the Closing Date) when due. 

        3    CONDITIONS OF LOANS    

        3.1    Conditions Precedent to Initial Credit Extension.    The obligation of Bank to make the initial Credit
Extension is subject to the condition precedent that Bank shall have received, in form and substance satisfactory to Bank, the following: 

                (a)  this
Agreement; 

                (b)  a
certificate of the Secretary of Borrower with respect to articles, bylaws, incumbency and resolutions authorizing the execution and delivery of this Agreement; 

                (c)  Negative
Pledge Agreement covering Intellectual Property; 

                (d)  landlord's
waiver; 

                (e)  a
legal opinion of Borrower's counsel, in form and substance acceptable to Bank; 

                (f)    Pledge
Agreement; 

                (g)  financing
statements (Forms UCC-1); 

                (h)  Account
Control Agreement/ Investment Account Control Agreement; 

                (i)    Confirmation
of Payoff of Fleet Bank loan; 

                (j)    insurance
certificate; 

                (k)  payment
of the fees and Bank Expenses then due specified in Section 2.4 hereof; 

                (l)    Certificate
of Foreign Qualification (if applicable); 

                (m)  Certificate
of Good Standing/Legal Existence; and 

                (n)  such
other documents, and completion of such other matters, as Bank may reasonably deem necessary or appropriate. 

        3.2    Conditions Precedent to all Credit Extensions.    Bank's obligations to make each Credit Extension, including
the initial Credit Extension, is subject to the following: 

                (a)  timely
receipt of any Payment/Advance Form; and 

4

 

                (b)  the
representations and warranties in Section 5 shall be materially true on the date of the Payment/Advance Form and on the effective date of each Credit
Extension and no Event of Default
shall have occurred and be continuing, or result from the Credit Extension. Each Credit Extension is Borrower's representation and warranty on that date that the representations and warranties in
Section 5 remain true. 

        4    CREATION OF SECURITY INTEREST    

        4.1    Grant of Security Interest.    Borrower hereby grants Bank, to secure the payment and performance in full of
all of the Obligations and the performance of each of Borrower's duties under the Loan Documents, a continuing security interest in, and pledges and assigns to the Bank, the Collateral, wherever
located, whether now owned or hereafter acquired or arising, and all proceeds and products thereof. Borrower warrants and represents that the security interest granted herein shall be a first priority
security interest in the Collateral. Bank may place a "hold" on any deposit account pledged as Collateral. 

        Except
as disclosed on the Schedule, Borrower is not a party to, nor is bound by, any license or other agreement with respect to which the Borrower is the licensee that prohibits or
otherwise restricts Borrower from granting a security interest in Borrower's interest in such license or agreement or any other property. Without prior consent from Bank, Borrower shall not enter
into, or become bound by, any such license or agreement which is reasonably likely to have a material impact on Borrower's business or financial condition. Borrower shall take such steps as Bank
reasonably requests to obtain the consent of, or waiver by, any person whose consent or waiver is necessary for all such licenses or contract rights to be deemed "Collateral" and for Bank to have a
security interest in it that might otherwise be restricted or prohibited by law or by the terms of any such license or agreement, whether now existing or entered into in the future. 

        Borrower
agrees that any disposition of the Collateral in violation of this Agreement, by either the Borrower or any other Person, shall be deemed to violate the rights of the Bank under
the Code. If the Agreement is terminated, Bank's lien and security interest in the Collateral shall continue until Borrower fully satisfies its Obligations. If Borrower shall at any time, acquire a
commercial tort claim, Borrower shall promptly notify Bank in a writing signed by Borrower of the brief details thereof and grant to Bank in such writing a security interest therein and in the
proceeds thereof, all upon the terms of this Agreement, with such writing to be in form and substance satisfactory to Bank. 

        5    REPRESENTATIONS AND WARRANTIES    

        Borrower
represents and warrants as follows: 

        5.1    Due Organization and Authorization.    Borrower and each Subsidiary is duly existing and in good standing in
its state of formation and qualified and licensed to do business in, and in good standing in, any state in which the conduct of its business or its ownership of property requires that it be qualified
except where the failure to do so could not reasonably be expected to cause a Material Adverse Change. In connection with this Agreement, the Borrower delivered to the Bank a certificate signed by the
Borrower and entitled "Perfection Certificate". The Borrower represents and warrants to the Bank that: (a) the Borrower's exact legal name is that indicated on the Perfection Certificate and on
the signature page hereof; and (b) the Borrower is an organization of the type, and is organized in the jurisdiction, set forth in the Perfection Certificate; and (c) the Perfection
Certificate accurately sets forth the Borrower's organizational identification number or accurately states that the Borrower has none; and (d) the Perfection Certificate accurately sets forth
the Borrower's place of business, or, if more than one, its chief executive office as well as the Borrower's mailing address if different, and (e) all other information set forth on the
Perfection Certificate pertaining to the Borrower is accurate and complete. If the Borrower does not now have an organizational identification number, but later obtains one, Borrower shall forthwith
notify the Bank of such organizational identification number. 

5

 

        The
execution, delivery and performance of the Loan Documents have been duly authorized, and do not conflict with Borrower's organizational documents, nor constitute an event of default
under any material agreement by which Borrower is bound. Borrower is not in default under any agreement to which or by which it is bound in which the default could reasonably be expected to cause a
Material Adverse Change. 

        5.2    Collateral.    Borrower has good title to the Collateral, free of Liens except Permitted Liens. Borrower has no
deposit account, other than the deposit accounts with Bank and deposit accounts described in the Perfection Certificate delivered to the Bank in connection herewith. The Accounts are bona fide,
existing obligations, and the service or property has been performed or delivered to the account debtor or its agent for immediate shipment to and unconditional acceptance by the account debtor. The
Collateral is not in the possession of any third party bailee (such as a warehouse). In the event that Borrower, after the date hereof, intends to store or otherwise deliver any portion of the
Collateral to a bailee, then Borrower will first receive the written consent of Bank and such bailee must acknowledge in writing that the bailee is holding such Collateral for the benefit of Bank.
Borrower has no knowledge of any actual or imminent Insolvency Proceeding of any account debtor whose accounts are an Eligible Account in any Borrowing Base Certificate. All Inventory is in all
material respects of good and marketable quality, free from material defects. 

        5.3    Litigation.    Except as shown in the Schedule, there are no actions or proceedings pending or, to the
knowledge of Borrower's Responsible Officers, threatened by or against Borrower or any Subsidiary in which an adverse decision could reasonably be expected to cause a Material Adverse Change. 

        5.4    No Material Deviation in Financial Statements.    All consolidated financial statements for Borrower and any
Subsidiary delivered to Bank fairly present in all material respects Borrower's consolidated financial condition and Borrower's consolidated results of operations. There has not been any material
deterioration in Borrower's consolidated financial condition since the date of the most recent financial statements submitted to Bank. 

        5.5    Solvency.    Borrower is able to pay its debts (including trade debts) as they mature. 

        5.6    Regulatory Compliance.    Borrower is not an "investment company" or a company "controlled" by an "investment
company" under the Investment Company Act. Borrower is not engaged as one of its important activities in extending credit for margin stock (under Regulations T and U of the Federal Reserve Board of
Governors). Borrower has complied in all material respects with the Federal Fair Labor Standards Act. Borrower has not violated any laws, ordinances or rules, the violation of which could reasonably
be expected to cause a Material Adverse Change. None of Borrower's or any Subsidiary's properties or assets has been used by Borrower or any Subsidiary or, to the best of Borrower's knowledge, by
previous Persons, in disposing, producing, storing, treating, or transporting any hazardous substance other than legally. Borrower and each Subsidiary has timely filed all required tax returns and
paid, or made adequate provision to pay, all material taxes, except those being contested in good faith with adequate reserves under GAAP. Borrower and each Subsidiary has obtained all consents,
approvals and authorizations of, made all declarations or filings with, and given all notices to, all government authorities that are necessary to continue its business as currently conducted except
where the failure to make such declarations, notices or filings would not reasonably be expected to cause a Material Adverse Change. 

        5.7    Subsidiaries.    Borrower does not own any stock, partnership interest or other equity securities except for
Permitted Investments. 

        5.8    Full Disclosure.    No written representation, warranty or other statement of Borrower in any certificate or
written statement given to Bank taken together with all such written certificates and written statements given to Bank contains any untrue statement of a material fact or omits to state a 

6

 

material fact necessary to make the statements contained in the certificates or statements not misleading (it being recognized by Bank that the projections and forecasts provided by Borrower in good
faith and based upon reasonable assumptions are not viewed as facts and that actual results during the period or periods covered by such projections and forecasts may differ from the projected or
forecasted results). 

        6    AFFIRMATIVE COVENANTS    

        Borrower
shall do all of the following: 

        6.1    Government Compliance.    Borrower shall maintain its and all Subsidiaries' legal existence and good standing
in its jurisdiction of formation and maintain qualification in each jurisdiction in which the failure to so qualify would reasonably be expected to have a material adverse effect on Borrower's
business or operations. Borrower shall comply, and have each Subsidiary comply, with all laws, ordinances and regulations to which it is subject, noncompliance with which could have a material adverse
effect on Borrower's business or operations or be expected to cause a Material Adverse Change. 

        6.2    Financial Statements, Reports, Certificates.    

                (a)  Borrower
shall deliver to Bank: (i) quarterly, no later than five (5) days after filing with the Securities and Exchange Commission, a company prepared
consolidated balance sheet and income statement covering Borrower's consolidated operations during the period certified by a Responsible Officer and in a form acceptable to Bank together with a
Compliance Certificate signed by a Responsible Officer in the form of Exhibit C; (ii) annually, no later than five (5) days filing
with the Securities and Exchange Commission audited consolidated financial statements prepared under GAAP, consistently applied, together with an unqualified opinion on the financial statements from
an independent certified public accounting firm reasonably acceptable to Bank; (iii) within five (5) days of filing, copies of all statements, reports and notices made available to
Borrower's security holders or to any holders of Subordinated Debt and all reports on Form 10-K, 10-Q and 8-K filed with the Securities and Exchange
Commission; (iv) a prompt report of any legal actions pending or threatened against Borrower or any Subsidiary that could result in a judgement against Borrower or any Subsidiary of One Hundred
Thousand Dollars ($100,000.00) or more; and (vi)other financial information reasonably requested by Bank. 

        6.3    Inventory; Returns.    Borrower shall keep all Inventory in good and marketable condition, free from material
defects. Returns and allowances between Borrower and its account debtors shall follow Borrower's customary practices as they exist at the Closing Date. Borrower must promptly notify Bank of all
returns, recoveries, disputes and claims that involve more than Fifty Thousand Dollars ($50,000.00). 

        6.4    Taxes.    Borrower shall make, and cause each Subsidiary to make, timely payment of all material federal,
state, and local taxes or assessments (other than taxes and assessments which Borrower is contesting in good faith, with adequate reserves maintained in accordance with GAAP) and will deliver to Bank,
on demand, appropriate certificates attesting to such payments. 

        6.5    Insurance.    Borrower shall keep its business and the Collateral insured for risks and in amounts, standard
for Borrower's industry, and as Bank may reasonably request in Bank's reasonable discretion. Insurance policies shall be in a form, with companies, and in amounts that are satisfactory to Bank. All
property policies shall have a lender's loss payable endorsement showing Bank as an additional loss payee and all liability policies shall show the Bank as an additional insured and all policies shall
provide that the insurer must give Bank at least twenty (20) days notice before canceling its policy. At Bank's request, Borrower shall deliver certified copies of policies and evidence of all
premium payments. Proceeds payable under any policy shall, at Bank's option, be payable to Bank on account of the Obligations. Notwithstanding the foregoing, so long as no Event of Default has
occurred 

7

 

and is continuing, Borrower shall have the option of applying the proceeds of any casualty policy up to $25,000.00, in the aggregate, toward the replacement or repair of destroyed or damaged
property; provided that (i) any such replaced or repaired property (a) shall be of equal or like value as the replaced or repaired Collateral and (b) shall be deemed Collateral in
which Bank has been granted a first priority security interest and (ii) after the occurrence and during the continuation of an Event of Default all proceeds payable under such casualty policy
shall, at the option of the Bank, be payable to Bank on account of the Obligations. If Borrower fails to obtain insurance as required under Section 6.5 or to pay any amount or furnish any
required proof of payment to third persons and the Bank, Bank may make all or part of such payment or obtain such insurance policies required in Section 6.5, and take any action under the
policies Bank deems prudent. 

        6.6    Primary Accounts.    In order to permit the Bank to monitor the Borrower's financial performance and condition,
Borrower shall maintain its primary depository and operating accounts with Bank. In addition to the foregoing, on the Closing Date, and at all times thereafter, Borrower and its wholly owned
Subsidiaries shall maintain not less than Ten Million Dollars ($10,000,000.00) in unrestricted cash or securities, in accounts with the Bank or a Bank subsidiary, directed by Bank. In addition, for
each such account that the Borrower at any time opens or maintains, Borrower shall, at the Bank's request and option, pursuant to an agreement in form and substance acceptable to the Bank, cause the
depositary bank or securities intermediary to agree that such account is the collateral of the Bank pursuant to the terms hereunder. The provisions of this paragraph shall not apply to deposit
accounts exclusively used for payroll, payroll taxes and other employee wage and benefit payments to or for the benefit of the Borrower's employees. 

        6.7    Financial Covenants.    

        Borrower
shall maintain at all times, to be tested as of the last day of each quarter, unless otherwise noted:

                (a)    Liquidity.    Borrower and its Subsidiaries shall maintain unrestricted cash and marketable securities less
outstanding Obligations under the Committed Revolving Line, of not less than Twenty-Five Million Dollars ($25,000,000.00). If, at any time, the Borrower shall fail to satisfy the terms of
this Section 6.7(a), then the Borrower shall immediately deposit with the Bank an amount of unrestricted cash equal to the outstanding Obligations hereunder, and shall thereafter maintain
unrestricted cash with the Bank equal to the outstanding Obligations, as such amount may increase or decrease. 

        6.8    Further Assurances.    Borrower shall execute any further instruments and take further action as Bank
reasonably requests to perfect or continue Bank's security interest in the Collateral or to effect the purposes of this Agreement. 

        7    NEGATIVE COVENANTS    

        Borrower
shall not do any of the following without the Bank's prior written consent which shall not be unreasonably withheld. 

        7.1    Dispositions.    Convey, sell, lease, transfer or otherwise dispose of (collectively a "Transfer"), or permit
any of its Subsidiaries to Transfer, all or any part of its business or property, except for Transfers (i) of Inventory in the ordinary course of business; (ii) of
non-exclusive licenses and similar arrangements for the use of the property of Borrower or its Subsidiaries in the ordinary course of business; or (iii) of worn-out or
obsolete Equipment. 

        7.2    Changes in Business, Ownership, Management or Business Locations.    Engage in or permit any of its
Subsidiaries to engage in any business other than the businesses currently engaged in by Borrower or have a change in management such that Geoffrey F. Cox, for any reason, shall cease to be the chief
executive officer of the Borrower, and no successor thereto, acceptable to the Bank in its reasonable 

8

 

discretion, having experience, knowledge and biotechnology industry relationships equivalent to such officer, shall have been engaged and shall have commenced to perform the duties of such officer
within ninety (90) days after such cessation (the name of any such acceptable successor who shall have been so engaged and shall have commenced performance of such duties within such period
shall be deemed to have been inserted in place of the former officer in this clause). Borrower shall not, without at least thirty (30) days prior written notice to Bank: (i) relocate its
chief executive office, or add any new offices or business locations (unless such new offices or business locations contain less than Five Thousand Dollars ($5,000.00) in Borrower's assets or
property), or (ii) change its jurisdiction of organization, or (iii) change its organizational structure or type, or (iv) change its legal name, or (v) change any
organizational number (if any) assigned by its jurisdiction of organization. 

        7.3    Mergers or Acquisitions.    Merge or consolidate, or permit any of its Subsidiaries to merge or consolidate,
with any other Person, or acquire, or permit any of its Subsidiaries to acquire, all or substantially all of the capital stock or property of another Person. A Subsidiary may merge or consolidate into
another Subsidiary or into Borrower. 

        7.4    Indebtedness.    Create, incur, assume, or be liable for any Indebtedness, or permit any Subsidiary to do so,
other than Permitted Indebtedness. 

        7.5    Encumbrance.    Create, incur, or allow any Lien on any of its property, or assign or convey any right to
receive income, including the sale of any Accounts, or permit any of its Subsidiaries to do so, except for Permitted Liens, or permit any Collateral not to be subject to the first priority security
interest granted herein. The Collateral may also be subject to Permitted Liens. 

        7.6    Distributions; Investments.    (i) Directly or indirectly acquire or own any Person, or make any
Investment in any Person, other than Permitted Investments, or permit any of its Subsidiaries to do so; or (ii) pay any dividends or make any distribution or payment or redeem, retire or
purchase any capital stock. 

        7.7    Transactions with Affiliates.    Directly or indirectly enter or permit any material transaction with any
Affiliate, except transactions that are in the ordinary course of Borrower's business, upon fair and reasonable terms that are no less favorable to Borrower than would be obtained in an arm's length
transaction with a non-affiliated Person. 

        7.8    Subordinated Debt.    Make or permit any payment on any Subordinated Debt, except under the terms of the
Subordinated Debt, or amend any provision in any document relating to the Subordinated Debt, without Bank's prior written consent. 

        7.9    Compliance.    Become an "investment company" or a company controlled by an "investment company", under the
Investment Company Act of 1940 or undertake as one of its important activities extending credit to purchase or carry margin stock, or use the proceeds of any Credit Extension for that purpose; fail to
meet the minimum funding requirements of ERISA, permit a Reportable Event or Prohibited Transaction, as defined in ERISA, to occur; fail to comply with the Federal Fair Labor Standards Act or violate
any other law or regulation, if the violation could reasonably be expected to have a material adverse effect on Borrower's business or operations or would reasonably be expected to cause a Material
Adverse Change, or permit any of its Subsidiaries to do so. 

        8    EVENTS OF DEFAULT    

        Any
one of the following is an Event of Default: 

        8.1    Payment Default.    Borrower fails to pay any of the Obligations within three (3) days after their due
date. During the additional period the failure to cure the default is not an Event of Default (but no Credit Extension shall be made during the cure period); 

9

 

        8.2    Covenant Default.    Borrower does not perform any obligation in Section 6 or violates any covenant in
Section 7 or does not perform or observe any other material term, condition or covenant in this Agreement, any Loan Documents, or in any agreement between Borrower and Bank and as to any
default under a term, condition or covenant that can be cured, has not cured the default within ten (10) days after it occurs, or if the default cannot be cured within ten (10) days or
cannot be cured after Borrower's attempts in the ten (10) day period, and the default may be cured within a reasonable time,
then Borrower shall have additional time, (of not more than thirty (30) days) to attempt to cure the default. Grace periods provided under this section shall not apply, among other things, to
financial covenants or any other covenants that are required to be satisfied, completed or tested by a date certain. During the additional period the failure to cure the default is not an Event of
Default (but no Credit Extensions shall be made during the cure period); 

        8.3    Material Adverse Change.    A Material Adverse Change occurs; 

        8.4    Attachment.    (i) Any material portion of Borrower's assets is attached, seized, levied on, or comes
into possession of a trustee or receiver and the attachment, seizure or levy is not removed in ten (10) days; (ii) the service of process upon the Borrower seeking to attach, by trustee
or similar process any funds of the Borrower on deposit with the Bank; (iii) Borrower is enjoined, restrained, or prevented by court order from conducting a material part of its business;
(iv) a judgment or other claim becomes a Lien on a material portion of Borrower's assets; or (v) a notice of lien, levy, or assessment is filed against any of Borrower's assets by any
government agency and not paid within ten (10) days after Borrower receives notice. These are not Events of Default if stayed or if a bond is posted pending contest by Borrower (but no Credit
Extensions shall be made during the cure period); 

        8.5    Insolvency.    (i) Borrower becomes insolvent; (ii) Borrower begins an Insolvency Proceeding; or
(iii) an Insolvency Proceeding is begun against Borrower and not dismissed or stayed within forty-five (45) days (but no Credit Extensions shall be made before any Insolvency
Proceeding is dismissed); 

        8.6    Other Agreements.    If there is a default in any agreement to which Borrower is a party with a third party or
parties resulting in a right by such third party or parties, whether or not exercised, to accelerate the maturity of any Indebtedness in an amount in excess of One Hundred Thousand Dollars ($100,000)
or that could result in a Material Adverse Change; 

        8.7    Judgments.    If a judgment or judgments for the payment of money in an amount, individually or in the
aggregate, of at least Two Hundred Thousand Dollars ($200,000) shall be rendered against Borrower and shall remain unsatisfied and unstayed for a period of ten (10) days (provided that no
Credit Extensions will be made prior to the satisfaction or stay of such judgment); 

        8.8    Misrepresentations.    If Borrower or any Person acting for Borrower makes any material misrepresentation or
material misstatement now or later in any warranty or representation in this Agreement or in any writing delivered to Bank or to induce Bank to enter this Agreement or any Loan Document; 

Guaranty.  

                (i) Any
guaranty of any Obligations terminates or ceases for any reason to be in full force; or (ii) any Guarantor does not perform any obligation under any guaranty of
the Obligations; or (iii) any material misrepresentation or material misstatement exists now or later in any warranty or representation in any guaranty of the Obligations or in any certificate
delivered to Bank in connection with the guaranty; or (iv) any circumstance described in Section 7, or Sections 8.4, 8.5 or 8.7 occurs to any Guarantor, or (v) the death,
liquidation, winding up, termination of existence, or insolvency of any Guarantor. 

10

   
        9    BANK'S RIGHTS AND REMEDIES    

        9.1    Rights and Remedies.    When an Event of Default occurs and continues Bank may, without notice or demand, do
any or all of the following: 

                (a)  Declare
all Obligations immediately due and payable (but if an Event of Default described in Section 8.5 occurs all Obligations are immediately due and payable
without any action by Bank); 

                (b)  Stop
advancing money or extending credit for Borrower's benefit under this Agreement or under any other agreement between Borrower and Bank; 

                (c)  Settle
or adjust disputes and claims directly with account debtors for amounts, on terms and in any order that Bank considers advisable; 

                (d)  Make
any payments and do any acts it considers necessary or reasonable to protect its security interest in the Collateral. Borrower shall assemble the Collateral if
Bank requests and make it available as Bank designates. Bank may enter premises where the Collateral is located, take and maintain possession of any part of the Collateral, and pay, purchase, contest,
or compromise any Lien which appears to be prior or superior to its security interest and pay all expenses incurred. Borrower grants Bank a license to enter and occupy any of its premises, without
charge, to exercise any of Bank's rights or remedies; 

                (e)  Apply
to the Obligations any (i) balances and deposits of Borrower it holds, or (ii) any amount held by Bank owing to or for the credit or the account of
Borrower; 

                (f)    Ship,
reclaim, recover, store, finish, maintain, repair, prepare for sale, advertise for sale, and sell the Collateral. Bank is granted a non-exclusive,
royalty-free license or other right to use, without charge, Borrower's labels, patents, copyrights, mask works, rights of use of any name, trade secrets, trade names, trademarks, service
marks, and advertising matter, or any similar property as it pertains to the Collateral, in completing production of, advertising for sale, and selling any Collateral and, in
connection with Bank's exercise of its rights under this Section, Borrower's rights under all licenses and all franchise agreements inure to Bank's benefit; and 

                (g)  Dispose
of the Collateral according to the Code. 

        9.2    Power of Attorney.    Borrower hereby irrevocably appoints Bank as its lawful
attorney-in-fact, to be effective upon the occurrence and during the continuance of an Event of Default, to: (i) endorse Borrower's name on any checks or other forms of
payment or security; (ii) sign Borrower's name on any invoice or bill of lading for any Account or drafts against account debtors; (iii) settle and adjust disputes and claims about the
Accounts directly with account debtors, for amounts and on terms Bank determines reasonable; (iv) make, settle, and adjust all claims under Borrower's insurance policies; and
(v) transfer the Collateral into the name of Bank or a third party as the Code permits. Borrower hereby appoints Bank as its lawful attorney-in-fact to sign Borrower's
name on any documents necessary to perfect or continue the perfection of any security interest regardless of whether an Event of Default has occurred until all Obligations have been satisfied in full
and Bank is under no further obligation to make Credit Extensions hereunder. Bank's foregoing appointment as Borrower's attorney in fact, and all of Bank's rights and powers, coupled with an interest,
are irrevocable until all Obligations have been fully repaid and performed and Bank's obligation to provide Credit Extensions terminates. 

        9.3    Accounts Collection.    In the event that an Event of Default occurs and is continuing, Bank may notify any
Person owing Borrower money of Bank's security interest in the funds and verify and/or collect the amount of the Account. After the occurrence of an Event of Default, any amounts received by Borrower
shall be held in trust by Borrower for Bank, and, if requested by Bank, Borrower shall 

11

 

immediately deliver such receipts to Bank in the form received from the account debtor, with proper endorsements for deposit. 

        9.4    Bank Expenses.    Any amounts paid by Bank as provided herein are Bank Expenses and are immediately due and
payable, and shall bear interest at the then applicable rate and be secured by the Collateral. No payments by Bank shall be deemed an agreement to make similar payments in the future or Bank's waiver
of any Event of Default. 

        9.5    Bank's Liability for Collateral.    So long as the Bank complies with reasonable banking practices regarding
the safekeeping of collateral, the Bank shall not be liable or responsible for: (a) the safekeeping of the Collateral; (b) any loss or damage to the Collateral; (c) any diminution
in the value of the Collateral; or (d) any act or default of any carrier, warehouseman, bailee, or other person. Borrower bears all risk of loss, damage or destruction of the Collateral. 

        9.6    Remedies Cumulative.    Bank's rights and remedies under this Agreement, the Loan Documents, and all other
agreements are cumulative. Bank has all rights and remedies provided under the Code, by
law, or in equity. Bank's exercise of one right or remedy is not an election, and Bank's waiver of any Event of Default is not a continuing waiver. Bank's delay is not a waiver, election, or
acquiescence. No waiver hereunder shall be effective unless signed by Bank and then is only effective for the specific instance and purpose for which it was given. 

        9.7    Demand Waiver.    Borrower waives demand, notice of default or dishonor, notice of payment and nonpayment,
notice of any default, nonpayment at maturity, release, compromise, settlement, extension, or renewal of accounts, documents, instruments, chattel paper, and guarantees held by Bank on which Borrower
is liable. 

        10    NOTICES    

        All
notices or demands by any party to this Agreement or any other related agreement must be in writing and be personally delivered or sent by an overnight delivery service, by certified
mail, postage prepaid, return receipt requested, or by telefacsimile at the addresses listed below. Either Bank or Borrower may change its notice address by giving the other written notice. 

	If to Borrower:	Genzyme Transgenics Corporation

175 Crossing Boulevard, Suite 410

Framingham, Massachusetts 01702

Attn: Chief Executive Officer

FAX: (508) 270-2303
	

with a copy to:	

Palmer & Dodge LLP

111 Huntington Avenue at Prudential Center

Boston, Massachusetts 02199-7613

Attn.: Nathaniel S. Gardiner, Esquire

Fax: (617) 227-4420
	

If to Bank:	

Silicon Valley Bank

One Newton Executive Park, Suite 200

2221 Washington Street

Newton, Massachusetts 02462

Attn: Ms. Jane Braun

Fax: (617) 969-4395
	
 	

 

12

 

	

with a copy to:	

Riemer & Braunstein LLP

Three Center Plaza

Boston, Massachusetts 02108

Attn: David A. Ephraim, Esquire

FAX: (617) 880-3456

        11    CHOICE OF LAW, VENUE AND JURY TRIAL WAIVER    

        Massachusetts
law governs the Loan Documents without regard to principles of conflicts of law. Borrower and Bank each submit to the exclusive jurisdiction of the State and Federal courts
in Massachusetts; provided, however, that if for any reason Bank cannot avail itself of such courts in the Commonwealth of Massachusetts, Borrower accepts jurisdiction of the courts and venue in Santa
Clara County, California. NOTWITHSTANDING THE FOREGOING, THE BANK SHALL HAVE THE RIGHT TO BRING ANY ACTION OR PROCEEDING AGAINST THE BORROWER OR ITS PROPERTY IN THE COURTS OF ANY OTHER JURISDICTION
WHICH THE BANK DEEMS NECESSARY OR APPROPRIATE IN ORDER TO REALIZE ON THE COLLATERAL OR TO OTHERWISE ENFORCE THE BANK'S RIGHTS AGAINST THE BORROWER OR ITS PROPERTY. 

BORROWER AND BANK EACH WAIVE THEIR RIGHT TO A JURY TRIAL OF ANY CLAIM OR CAUSE OF ACTION ARISING OUT OF OR BASED UPON THIS AGREEMENT, THE LOAN DOCUMENTS OR ANY CONTEMPLATED
TRANSACTION, INCLUDING CONTRACT, TORT, BREACH OF DUTY AND ALL OTHER CLAIMS. THIS WAIVER IS A MATERIAL INDUCEMENT FOR BOTH PARTIES TO ENTER INTO THIS AGREEMENT. EACH PARTY HAS REVIEWED THIS WAIVER WITH
ITS COUNSEL.

        12    GENERAL PROVISIONS    

        12.1    Successors and Assigns.    This Agreement binds and is for the benefit of the successors and permitted assigns
of each party. Borrower may not assign this Agreement or any rights or Obligations under it without Bank's prior written consent which may be granted or withheld in Bank's discretion. Bank has the
right, without the consent of or notice to Borrower, to sell, transfer, negotiate, or grant participation in all or any part of, or any interest in, Bank's obligations, rights and benefits under this
Agreement, the Loan Documents or any related agreement. 

        12.2    Indemnification.    Borrower hereby indemnifies, defends and holds the Bank and its officers, employees and
agents harmless against: (a) all obligations, demands, claims, and liabilities asserted by any other party in connection with the transactions contemplated by the Loan Documents; and
(b) all losses or Bank Expenses incurred, or paid by Bank from, following, or consequential to transactions between Bank and Borrower (including reasonable attorneys' fees and expenses), except
for losses caused by Bank's gross negligence or willful misconduct. 

        12.3    Right of Set-Off.    Borrower and any guarantor hereby grant to Bank, a lien, security interest
and right of setoff as security for all Obligations to Bank, whether now existing or hereafter arising upon and against all deposits, credits, collateral and property, now or hereafter in the
possession, custody, safekeeping or control of Bank or any entity under the control of the Bank or in transit to any of them. At any time after the occurrence and during the continuance of an Event of
Default, without demand or notice, Bank may set off the same or any part thereof and apply the same to any liability or obligation of Borrower and any guarantor even though unmatured and regardless of
the adequacy of any other collateral securing the Obligations. ANY AND ALL RIGHTS TO REQUIRE BANK TO EXERCISE ITS RIGHTS OR REMEDIES WITH RESPECT TO ANY OTHER COLLATERAL WHICH SECURES THE OBLIGATIONS,
PRIOR TO EXERCISING ITS RIGHT OF SETOFF WITH RESPECT TO SUCH DEPOSITS, CREDITS OR OTHER PROPERTY OF THE 

13

 

BORROWER OR ANY GUARANTOR, ARE HEREBY KNOWINGLY, VOLUNTARILY AND IRREVOCABLY WAIVED. 

        12.4    Time of Essence.    Time is of the essence for the performance of all Obligations in this Agreement. 

        12.5    Severability of Provision.    Each provision of this Agreement is severable from every other provision in
determining the enforceability of any provision. 

        12.6    Amendments in Writing; Integration.    All amendments to this Agreement must be in writing signed by both Bank
and Borrower. This Agreement and the Loan Documents represent the entire agreement about this subject matter, and supersede prior negotiations or agreements. All prior agreements, understandings,
representations, warranties, and negotiations between the parties about the subject matter of this Agreement and the Loan Documents merge into this Agreement and the Loan Documents. 

        12.7    Counterparts.    This Agreement may be executed in any number of counterparts and by different parties on
separate counterparts, each of which, when executed and delivered, are an original, and all taken together, constitute one Agreement. 

        12.8    Survival.    All covenants, representations and warranties made in this Agreement continue in full force while
any Obligations remain outstanding. The obligation of Borrower in Section 12.2 to indemnify
Bank shall survive until the statute of limitations with respect to such claim or cause of action shall have run. 

        12.9    Confidentiality.    In handling any confidential information, Bank shall exercise the same degree of care that
it exercises for its own proprietary information, but disclosure of information may be made: (i) to Bank's subsidiaries or affiliates in connection with their business with Borrower;
(ii) to prospective transferees or purchasers of any interest in the Credit Extensions (provided, however, Bank shall use commercially reasonable efforts in obtaining such prospective
transferee's or purchaser's agreement to the terms of this provision); (iii) as required by law, regulation, subpoena, or other order, (iv) as required in connection with Bank's
examination or audit; and (v) as Bank considers appropriate in exercising remedies under this Agreement. Confidential information does not include information that either: (a) is in the
public domain or in Bank's possession when disclosed to Bank, or becomes part of the public domain after disclosure to Bank; or (b) is disclosed to Bank by a third party, if Bank does not know
that the third party is prohibited from disclosing the information. 

        13    DEFINITIONS    

        13.1    Definitions.    

        "Accounts" are all existing and later arising accounts, contract rights, and other obligations owed Borrower in connection with its sale
or lease of goods (including licensing software and other technology) or provision of services, all credit insurance, guaranties, other security and all merchandise returned or reclaimed by Borrower
and Borrower's Books relating to any of the foregoing, as such definition may be amended from time to time according to the Code. 

        "Advance" or "Advances" is a loan advance (or advances) under the Committed Revolving
Line. 

        "Affiliate" of a Person is a Person that owns or controls directly or indirectly the Person, any Person that controls or is controlled by
or is under common control with the Person, and each of that Person's senior executive officers, directors, partners and, for any Person that is a limited liability company, that Person's managers and
members. 

14

 

        "Bank Expenses" are all audit fees and expenses and reasonable costs or expenses (including reasonable attorneys' fees and expenses) for
preparing, negotiating, administering, defending and enforcing the Loan Documents (including appeals or Insolvency Proceedings). 

        "Borrower's Books" are all Borrower's books and records including ledgers, records regarding Borrower's assets or liabilities, the
Collateral, business operations or financial condition and all computer programs or discs or any equipment containing the information. 

        "Business Day" is any day that is not a Saturday, Sunday or a day on which the Bank is closed. 

        "Closing Date" is the date of this Agreement. 

        "Code" is the Uniform Commercial Code as adopted in Massachusetts, as amended and as may be amended and in effect from time to time. 

        "Collateral" is any and all properties, rights and assets of the Borrower granted by the Borrower to Bank or arising under the Code, now,
or in the future, in which the Borrower obtains an interest, or the power to transfer rights, including, without limitation, the property described on  Exhibit A. 

        "Committed Equipment Line" is an Equipment Advance or Equipment Advances of up to Four Million Dollars ($4,000,000.00) 

        "Committed Revolving Line" is an Advance or Advances of up to One Million Dollars ($1,000,000.00) 

        "Contingent Obligation" is, for any Person, any direct or indirect liability, contingent or not, of that Person for (i) any
indebtedness, lease, dividend, letter of credit or other obligation of another such as an obligation directly or indirectly guaranteed, endorsed, co-made, discounted or sold with recourse
by that Person, or for which that Person is directly or indirectly liable; (ii) any obligations for undrawn letters of credit for the account of that Person; and (iii) all obligations
from any interest rate, currency or commodity swap agreement, interest rate cap or collar agreement, or other agreement or arrangement designated to protect a Person against fluctuation in interest
rates, currency exchange rates or commodity prices; but "Contingent Obligation" does not include endorsements in the ordinary course of business. The amount of a Contingent Obligation is the stated or
determined amount of the primary obligation for which the Contingent Obligation is made or, if not determinable, the maximum reasonably anticipated liability for it determined by the Person in good
faith; but the amount may not exceed the maximum of the obligations under the guarantee or other support arrangement. 

        "Credit Extension" is each Advance, Equipment Advance, Letter of Credit, Term Loan, Exchange Contract, or any other extension of credit by
Bank for Borrower's benefit. 

        "Eligible Equipment" is (a) general purpose computer equipment, office equipment, test and laboratory equipment, furnishings,
subject to the limitations set forth herein, and (b) Other Equipment that complies with all of Borrower's representations and warranties to Bank and which is reasonably acceptable to Bank in
all respects. 

        "Equipment" is all present and future machinery, equipment, tenant improvements, furniture, fixtures, vehicles, tools, parts and
attachments in which Borrower has any interest. 

        "Equipment Advance" is defined in Section 2.1.4. 

        "Equipment Availability End Date" is defined in Section 2.1.4. 

        "Equipment Maturity Date" is defined in Section 2.1.4. 

        "ERISA" is the Employment Retirement Income Security Act of 1974, and its regulations. 

15

 

        "Fleet Payoff Amount" is a loan of Five Million Five Hundred Thousand Dollars ($5,500,000.00) for the refinance of all outstanding
indebtedness to Fleet Bank. 

        "FX Forward Contract" is defined in Section 2.1.3. 

        "FX Reserve" is defined in Section 2.1. 

        "GAAP" is generally accepted accounting principles. 

        "Guarantor" is any present or future guarantor of the Obligations. 

        "Indebtedness" is (a) indebtedness for borrowed money or the deferred price of property or services, such as reimbursement and
other obligations for surety bonds and letters of credit, (b) obligations evidenced by notes, bonds, debentures or similar instruments, (c) capital lease obligations and
(d) Contingent Obligations. 

        "Insolvency Proceeding" is any proceeding by or against any Person under the United States Bankruptcy Code, or any other bankruptcy or
insolvency law, including assignments for the benefit of creditors, compositions, extensions generally with its creditors, or proceedings seeking reorganization, arrangement, or other relief. 

        "Intellectual Property" is any copyright rights, copyright applications, copyright registrations and like protections in each work of
authorship and derivative work, whether published or unpublished, now owned or later acquired; any patents, trademarks, service marks and applications therefor; any trade secret rights, including any
rights to unpatented inventions, now owned or hereafter acquired. 

        "Inventory" is present and future inventory in which Borrower has any interest, including merchandise, raw materials, parts, supplies,
packing and shipping materials, work in process and finished products intended for sale or lease or to be furnished under a contract of service, of every kind and description now or later owned by or
in the custody or possession, actual or constructive, of Borrower, including inventory temporarily out of its custody or possession or in transit and including returns on any accounts or other
proceeds (including insurance proceeds) from the sale or disposition of any of the foregoing and any documents of title. 

        "Investment" is any beneficial ownership of (including stock, partnership interest or other securities) any Person, or any loan, advance
or capital contribution to any Person. 

        "Letter of Credit" means a letter of credit or similar undertaking issued by Bank pursuant to Section 2.1.2. 

        "Letter of Credit Reserve" has the meaning set forth in Section 2.1.2. 

        "Lien" is a mortgage, lien, deed of trust, charge, pledge, security interest or other encumbrance. 

        "Loan Amount" in respect of each Equipment Advance is the original principal amount of such Equipment Advance. 

        "Loan Documents" are, collectively, this Agreement, any note, or notes or guaranties executed by Borrower or Guarantor, and any other
present or future agreement between Borrower and/or for the benefit of Bank in connection with this Agreement, all as amended, extended or restated. 

        "Loan Supplement" is defined in Section 2.1.1(b) and attached as Exhibit B. 

        "Material Adverse Change " is: (i) A material impairment in the perfection or priority of Bank's security interest in the
Collateral or in the value of such Collateral; (ii) a material adverse change in the business, operations, or condition (financial or otherwise) of the Borrower; or (iii) a material 

16

 

impairment of the prospect of repayment of any portion of the Obligations; or (iv) Bank determines, based upon information available to it and in its reasonable judgment, that there is a
reasonable likelihood that Borrower shall fail to comply with one or more of the financial covenants in Section 6 during the next succeeding financial reporting period. 

        "Obligations" are debts, principal, interest, Bank Expenses and other amounts Borrower owes Bank now or later, including letters of
credit, cash management services, and foreign exchange contracts, if any, and including interest accruing after Insolvency Proceedings begin and debts, liabilities, or obligations of Borrower assigned
to Bank. 

        "Other Equipment" is leasehold improvements, transferable software licenses, and other similar property and soft costs approved by the
Bank, including sales tax, freight and installation expenses. Unless otherwise agreed to by Bank, not more than 25% of the proceeds of the Committed Equipment Line shall be used to finance Other
Equipment. 

        "Payment Date" is the first day of each calendar month. 

        "Permitted Indebtedness" is: 

                (a)  Borrower's
indebtedness to Bank under this Agreement or the Loan Documents; 

                (b)  Indebtedness
existing on the Closing Date and shown on the Schedule; 

                (c)  Subordinated
Debt; 

                (d)  Indebtedness
of the Subsidiaries of Borrower in amount not to exceed One Hundred Thousand Dollars ($100,000.00), in the aggregate, per year; 

                (e)  Indebtedness
to trade creditors incurred in the ordinary course of business; and 

                (f)    Indebtedness
secured by Permitted Liens; and 

                (g)  Extensions,
refinancings, modifications, amendments and restatements of any items of Permitted Indebtedness (a) through (f) above, provided that the
principal amount thereof is not increased or the terms thereof are not modified to impose more burdensome terms upon Borrower or its Subsidiary, as the case may be. 

        "Permitted Investments" are: 

                (a)  Investments
shown on the Investments Schedule and existing on the Closing Date; 

                (b)  (i) marketable
direct obligations issued or unconditionally guaranteed by the United States or its agency or any state maturing within 1 year from its
acquisition, (ii) commercial paper maturing no more than 1 year after its creation and having the highest rating from either Standard & Poor's Corporation or Moody's Investors
Service, Inc., (iii) Bank's certificates of deposit issued maturing no more than 1 year after issue, (iv) any other investments administered through the Bank; 

                (c)  Joint
venture with Pharming Group, N.V. for the operation of a transgenic production facility; and 

                (d)  Investments
in accordance with the Borrower's Investment Policy, attached hereto as Schedule B. 

        "Permitted Liens" are: 

                (a)  Liens
existing on the Closing Date and shown on the Schedule or arising under this Agreement or other Loan Documents; 

17

 

                (b)  Liens
for taxes, fees, assessments or other government charges or levies, either not delinquent or being contested in good faith and for which Borrower maintains
adequate reserves on its Books, if they have no priority over any of Bank's security interests; 

                (c)  Leases
or subleases and non-exclusive licenses or sublicenses granted in the ordinary course of Borrower's business, if the leases, subleases, licenses and
sublicenses permit granting Bank a security interest; 

                (e)  Liens
incurred in the extension, renewal or refinancing of the indebtedness secured by Liens described in (a) through (c), but any extension, renewal or
replacement Lien must be limited to the property encumbered by the existing Lien and the principal amount of the indebtedness may not increase; 

        "Person" is any individual, sole proprietorship, partnership, limited liability company, joint venture, company, trust, unincorporated
organization, association, corporation, institution, public benefit corporation, firm, joint stock company, estate, entity or government agency. 

        "Prime Rate" is Bank's most recently announced "prime rate," even if it is not Bank's lowest rate. Except as otherwise provided elsewhere
herein, any Credit Extension made hereunder based on the Bank's Prime Rate shall increase or decrease with the changes in the Bank's Prime Rate. 

        "Responsible Officer" is each of the Chief Executive Officer, President, Chief Financial Officer and Controller of Borrower. 

        "Revolving Maturity Date" is the date which is three hundred and sixty-four (364) days from the Closing Date. 

        "Schedule" is any attached schedule of exceptions. 

        "Subordinated Debt" is debt incurred by Borrower subordinated to Borrower's debt to Bank (pursuant to a subordination agreement entered
into between the Bank, the Borrower and the subordinated creditor), on terms acceptable to Bank. 

        "Subsidiary" is any Person, corporation, partnership, limited liability company, joint venture, or any other business entity of which more
than 50% of the voting stock or other equity interests is owned or controlled, directly or indirectly, by the Person or one or more Affiliates of the Person. 

        "Term Equipment Amount" is a loan in an amount of up to One Million One Hundred Thousand Dollars ($1,100,000.00). 

        "Term Loan" a loan of up to Six Million Six Hundred Thousand Dollars ($6,600,000.00), which constitutes the Fleet Payoff Amount and the
Term Equipment Amount. 

        "Total Liabilities" is on any day, obligations that should, under GAAP, be classified as liabilities on Borrower's consolidated balance
sheet, including all Indebtedness, and current portion of Subordinated Debt permitted by Bank to be paid by Borrower, but excluding all other Subordinated Debt. 

[Remainder
of Page Intentionally Left Blank] 

18

 

        IN
WITNESS WHEREOF, the parties hereto have caused this Agreement to be executed as a sealed instrument under the laws of the Commonwealth of Massachusetts as of the date first above
written. 

	BORROWER:	 	 
	

GENZYME TRANSGENICS CORPORATION	
 	

 
	

By: \s\ John B. Green	
 	

 
	

Name: John B. Green	
 	

 
	

Title: Senior Vice President	
 	

 
	

 BANK:	

 	

 
	

SILICON VALLEY BANK, d/b/a

SILICON VALLEY EAST	

 	

 
	

By: \s\ Michael J. Harewick	
 	

 
	

Name: Michael J. Harewick	
 	

 
	

Title: Senior Vice President	
 	

 
	

SILICON VALLEY BANK	

 	

 
	

By: \s\ Maggie Garcia	

 	

 
	

Name: Maggie Garcia	
 	

 
	

Title: Assistant Vice President	
 	

 
	

(Signed in Santa Clara County, California)	
 	

 

19

  

 
 

EXHIBIT A    
  

        The Collateral consists of all right, title and interest of Borrower in and to the following: 

        All
goods, equipment, inventory, contract rights or rights to payment of money, license agreements, franchise agreements, general intangibles (including payment intangibles), accounts
(including health-care receivables), documents, instruments (including any promissory notes), chattel paper (whether tangible or electronic), cash, deposit accounts, fixtures, letters of
credit rights (whether or not the letter of credit is evidenced by a writing), commercial tort claims, securities, and all other investment property supporting obligations, and financial assets,
whether now owned or hereafter acquired, wherever located; and 

        All
Borrower's Books relating to the foregoing and any and all claims, rights and interests in any of the above and all substitutions for, additions, attachments, accessories, accessions
and improvements to and replacements, products, proceeds and insurance proceeds of any or all of the foregoing. 

        The
Collateral does not include: 

        Any
copyright rights, copyright applications, copyright registrations and like protections in each work of authorship and derivative work, whether published or unpublished, now owned or
later acquired; any patents, trademarks, service marks and applications therefor; any trade secret rights, including any rights to unpatented inventions, now owned or hereafter acquired.
Notwithstanding the foregoing, the Collateral shall include all accounts, license and royalty fees and other revenues, proceeds, or income arising out of or relating to any of the foregoing
intellectual property. To the extent a court of competent jurisdiction holds that a security interest in any Intellectual Property is necessary to have a security interest in any accounts, license and
royalty fees and other revenues, proceeds, or income arising out of or relating to any of the foregoing Intellectual Property, then the Collateral shall, effective as of the Closing Date, include the
Intellectual Property, to the extent necessary to permit perfection of the Bank's security interest in such accounts, license and royalty fees and other revenues, proceeds, or income arising out of or
relating to any of the Intellectual Property. 

20

  

 
 
 

EXHIBIT B
  
    Loan Payment/Advance Request Form
  Deadline for same day processing is 3:00 E.S.T.    
  

	Fax To: (617) 969-5965	 	Date:	 
	 	 	 	

	LOAN PAYMENT:	 	 	 
	Sample documents Client Name (Borrower)
	From Account #	 	 	To Account #	 
	 	
	 	 	

	 	(Deposit Account #)	 	 	(Loan Account #)
	Principal $_____________________ and/or Interest $__________________________
	All Borrower's representation and warranties in the Loan and Security Agreement are true, correct and complete in all material respects to on the date of the telephone transfer request for and advance, but
those representations and warranties expressly referring to another date shall be true, correct and complete in all material respects as of the date:
	Authorized Signature:	 	 	Phone Number:	 
	 	
	 	 	

	LOAN ADVANCE:	 	 	 
	Complete Outgoing Wire Request section below if all or a portion of the funds from this loan advance are for an outgoing wire.
	From Account #	 	 	To Account #	 
	 	
	 	 	

	 	(Loan Account #)	 	 	(Deposit Account #)
	Amount of Advance $	 	 	 	 
	 	
	 	 	 
	All Borrower's representation and warranties in the Loan and Security Agreement are true, correct and complete in all material respects to on the date of the telephone transfer request for and advance, but
those representations and warranties expressly referring to another date shall be true, correct and complete in all material respects as of the date:
	Authorized Signature:	 	 	Phone Number:	 
	 	
	 	 	

	OUTGOING WIRE REQUEST	 	 	 
	Complete only if all or a portion of funds from the loan advance above are to be wired.
	Deadline for same day processing is 3:00pm, E.S.T.
	Beneficiary Name:	 	 	Amount of Wire: $	 
	 	
	 	 	

	Beneficiary Bank:	 	 	Account Number:	 
	 	
	 	 	

	City and Sate:	 	 	 	 
	 	
	 	 	 
	Beneficiary Bank Transit (ABA) #:	 	 	Beneficiary Bank Code (Swift, Sort, Chip, etc.):
	 	
	 	(For International Wire Only)
	Intermediary Bank:	 	 	Transit (ABA) #:	 
	 	
	 	 	

	For Further Credit to:	 	 	 	 
	 	
	 	 	 
	Special Instruction:	 	 	 	 
	 	

	        By signing below, I (we) acknowledge and agree that my (our) funds transfer request shall be processed in accordance with and subject to
the terms and conditions set forth in the agreements(s) covering funds transfer service(s), which agreements(s) were previously received and executed by me (us).
	Authorized Signature:	 	 	2nd Signature

(If Required):	 
	 	
	 	 	

	Print Name/Title:	 	 	Print Name/Title:	 
	 	
	 	 	

	Telephone #	 	 	Telephone #	 
	 	
	 	 	

21

  

 
 

EXHIBIT C
  COMPLIANCE CERTIFICATE    
  

TO:
SILICON VALLEY BANK 

        FROM:
GENZYME TRANSGENICS CORPORATION 

        The
undersigned authorized officer of Genzyme Transgenics Corporation certifies that under the terms and conditions of the Loan and Security Agreement between Borrower and Bank (the
"Agreement"), (i) Borrower is in complete compliance for the period
ending                                  with all required covenants except as
noted below and (ii) all representations and warranties
in the Agreement are true and correct in all material respects on this date. Attached are the required documents supporting the certification. The Officer certifies that these are prepared in
accordance with Generally Accepted Accounting Principles (GAAP) consistently applied from one period to the next except as explained in an accompanying letter or footnotes. The Officer acknowledges
that no borrowings may be requested at any time or date of determination that Borrower is not in compliance with any of the terms of the Agreement, and that compliance is determined not just at the
date this certificate is delivered. 

 Please indicate compliance status by circling Yes/No under "Complies" column.  

	Reporting Covenant
 
	 	Required
	 	 
	 	Complies

	Quarterly financial statements with CC	 	Within 5 days after filing with SEC	 	Yes	 	No
	Annual (CPA Audited)	 	With 5 days after filing with SEC	 	Yes	 	No

	Financial Covenant
 
	 	Required
	 	Actual
	 	Complies

	
Maintain on a Quarterly Basis:	
 	
 	

 	
 	
 	

 	
 	

 	
 	

 
	 	Minimum Liquidity	 	$	25,000,000.00	 	$	 	 	Yes	 	No

	Comments Regarding Exceptions: See Attached.	 	 	 
	 	 	BANK USE ONLY
	Sincerely,	 	Received by:	 
	 	 	 	
AUTHORIZED SIGNER
	
SIGNATURE	 	Date:	 
	 	 	 	

	 	 	Verified:	 
	
TITLE	 	 	
AUTHORIZED SIGNER
	 	 	Date:	 
	
DATE	 	 	

	 	 	Compliance Status: Yes No
	 	 	3	 

22

  

 
 

Schedule to Loan and Security Agreement    
  

The
exact correct corporate name of Borrower is (attach a copy of the formation documents, e.g., articles, partnership agreement): 

Borrower's
State of formation: 

Borrower
has operated under only the following other names (if none, so state): 

All
other address at which the Borrower does business are as follows (attach additional sheets if necessary and include all warehouse addresses): 

Borrower
has deposit accounts and/or investment accounts located only at the following institutions: 

List
Acct. Numbers: 

Liens
existing on the Closing Date and disclosed to and accepted by Bank in writing: 

Investments
existing on the Closing Date and disclosed to and accepted by Bank in writing: 

Subordinated Debt:  

Indebtedness
on the Closing Date and disclosed to and consented to by Bank in writing:            

The
following is a list of the Borrower's copyrights (including copyrights of software) which are registered with the United States Copyright Office. (Please include name of the copyright and
registration number and attach a copy of the registration): 

The
following is a list of all software which the Borrower sells, distributes or licenses to others, which is not registered with the United States Copyright Office. (Please include versions which are
not registered: 

The
following is a list of all of the Borrower's patents which are registered with the United States Patent Office. (Please include name of the patent and registration number and attach a copy of the
registration.): 

23

 

The
following is a list of all of the Borrower's patents which are pending with the United States Patent Office. (Please include name of the patent and a copy of the application.): 

The
following is a list of all of the Borrower's registered trademarks. (Please include name of the trademark and a copy of the registration.): 

Borrower
is not subject to litigation which would have a material adverse effect on the Borrower's financial condition, except the following (attach additional comments, if needed): 

Tax
ID Number _______________________________________________ 

Organizational
Number, if any: ______________________________ 

24

  

 
 

Schedule to Loan and Security Agreement    
  

The exact correct corporate name of Borrower is (attach a copy of the formation documents, e.g., articles, partnership agreement): Genzyme Transgenics
Corporation 

See
attached copy of Secretary's Certificate, which includes a copy of the Borrower's charter. 

Borrower's State of formation: Massachusetts 

Borrower has operated under only the following other names (if none, so state): None 

("GTC"
as possible d/b/a) 

All other address at which the Borrower does business are as follows (attach additional sheets if necessary and include all warehouse addresses):

87
New Spencer Road

Charlton Depot, MA 01509 

5
Mountain Road

Framingham, MA 01701 

1
Mountain Road

Framingham, MA 01701 

45
New York Avenue

Framingham, MA 01701 

25

 

Borrower has deposit accounts and/or investment accounts located only at the following institutions:

	GENZYME TRANSGENICS CORPORATION	 	 	 	 
	

Fleet Bank

100 Federal Street

Boston, MA 02110	
 	

551-49406	
 	

disbursement and payroll account
	

Fleet Bank

100 Federal Street

Boston, MA 02110	
 	

9417546122	
 	

cash concentration
	

Fleet Bank

100 Federal Street

Boston, MA 02110	
 	

9427660009	
 	

depository—zero balance
	

Fleet Bank

100 Federal Street

Boston, MA 02110	
 	

9417550818	
 	

disbursement—zero balance
	

Fleet Bank

One Federal Street

Boston, MA 02211	
 	

0008902070	
 	

investment account
	

Lehman

299 Park Avenue, 29th Floor

New York, NY 10171	
 	

831-35309-10 894	
 	

investment account
	

 GENZYME TRANSGENICS SECURITIES CORP	

 	

 	

 	

 
	

Fleet Bank

100 Federal Street

Boston, MA 02110	
 	

9428374987	
 	

investment broker account
	

Fleet Bank

100 Federal Street

Boston, MA 02110	
 	

0009180170	
 	

investment account
	

Lehman

299 Park Avenue, 29th Floor

New York, NY 10171	
 	

831-35317-10 894	
 	

investment account
	

 ATIII LLC	

 	

 	

 	

 
	

Fleet Bank

100 Federal Street

Boston, MA 02110	
 	

9427659921	
 	

operating account

Permitted Liens:  

Genzyme Transgenics Corporation  

Liens
on equipment leased pursuant to various operating leases of the Borrower and its Subsidiaries. 

26

 

Lien
on equipment leased pursuant to the Master Lease Agreement with Transamerica Business Credit Corporation dated December 30, 1996. 

Cash
collateral at Fleet Bank to secure the Borrower's line of credit, with face amount of $249,360.00. 

TSI Corporation  

Lien
on lab equipment, manufacturing equipment, furniture and fixtures leased pursuant to the Master Equipment Lease Agreement with Finova Technology Finance, Inc. (formerly Financing for
Science International, Inc.) dated September 27, 1994. 

Permitted Investments:  

Subsidiaries of GTC  

GTC
Cancer Vaccines, Inc.

200,000 shares common stock authorized

100 shares issued and outstanding—all held by GTC 

TSI
Corporation

Delaware

1,000 shares common stock authorized

200 shares issued and outstanding—all held by GTC 

Genzyme
Transgenics Securities Corporation

Massachusetts

200,000 shares common stock authorized

100 shares issued and outstanding—all held by GTC 

ATIII
LLC

Delaware

100% interest held by GTC 

GTC
Japan Limited

Japan

16,000 shares common stock authorized

11,777 shares issued and outstanding (22% held by GTC, 78% held by GTC Holding Ltd.) 

GTC
Holding Ltd.

Cayman Islands

50,000 shares common stock authorized

1 share issued and outstanding—held by GTC 

Subsidiaries of TSI  

TSI
Deutschland GmbH

Germany

100% held by TSI 

Transgenic
Investments, Inc.

Delaware

1,000 shares common stock authorized

1,000 shares issued and outstanding—all held by TSI 

Health
and Sciences Research Incorporated

Delaware

27

 

1,500 shares common stock authorized

1,500 shares preferred stock authorized—all held by TSI—to be dissolved 

Investments  

Lehman
Brothers Account invested pursuant to Investment Policy with a balance on 3/3/02 of $0 for GTC and $83,149,238.31 for Genzyme Transgenics Securities Corporation. 

Fleet
Account invested pursuant to Investment Policy with a balance on 3/3/02 of $58,695.59 for GTC and $$62,348.97 for Genzyme Transgenics Securities Corporation. 

Permitted Indebtedness:  

Genzyme Transgenics Corporation  

Master
Lease Agreement with Transamerica Business Credit Corporation dated December 30, 1996—amount outstanding $121,658.21 as of March 3, 2002. 

Letter
of Credit Issued by Fleet Bank in face amount of $249,360. 

TSI Corporation  

Master
Equipment Lease Agreement with Finova Technology Finance, Inc. (formerly Financing for Science International, Inc.) dated September 27, 1994—amount outstanding
$110,100.85 as of March 3, 2002. 

The following is a list of the Borrower's copyrights (including copyrights of software) which are registered with the United States Copyright Office. (Please include name of
the copyright and registration number and attach a copy of the registration): None. 

The following is a list of all software which the Borrower sells, distributes or licenses to others, which is not registered with the United States Copyright Office. Please
include versions which are not registered: None. 

The following is a list of all of the Borrower's patents which are registered with the United States Patent Office. (Please include name of the patent and registration number
and attach a copy of the registration.):

See
attached list of granted patent information. 

The following is a list of all of the Borrower's patents which are pending with the United States Patent Office. (Please include name of the patent and a copy of the
application.):

See
attached list of pending patent information. 

The following is a list of all of the Borrower's registered trademarks. (Please include name of the trademark and a copy of the registration.):  

See attached list of trademark information. 

Borrower is not subject to litigation which would have a material adverse effect on the Borrower's financial condition, except the following (attach additional comments, if
needed):

Dearlove, et al. v. GTC  

On
November 13, 2001, GTC was sued in a purported class action in the Court of Common Pleas, Philadelphia County, Pennsylvania. The named plaintiffs are George Dearlove and Annaregina Roberts,
two employees of Primedica Argus Research Laboratories, a wholly owned subsidiary of Primedica Corporation; Primedica was a wholly owned subsidiary of GTC until February 26, 2001, when GTC sold 

28

 

Primedica to Charles River Laboratories International, Inc. When Primedica was a subsidiary of GTC, the employees of Primedica and its subsidiaries were eligible to participate in GTC's
incentive stock option plan (specifically, the 1993 Equity Incentive Plan, or the "Plan"). When GTC sold Primedica to Charles River Laboratories, it took the position that the employees of Primedica
and its subsidiaries had been "terminated" as employees of GTC or its affiliates for purposes of the Plan. GTC informed the affected employees, notifying them that pursuant to the Plan any outstanding
options would expire 90 days after the sale of Primedica had closed. The purported plaintiff class is "all employees of Primedica Corporation and its subsidiaries who, as of February 7,
2001 [the date GTC announced the impending sale of Primedica], had been awarded stock options [pursuant to the Plan] and who had not yet exercised their
options." The plaintiffs contend that they have not been "terminated" within the meaning of the Plan; that their options have not expired; that GTC breached an implied covenant of good faith and fair
dealing with the plaintiffs by selling Primedica without making provision for its employees as holders of stock options and thereafter taking the position that the GTC options expired 90 days
after the sale; and that GTC was unjustly enriched by receiving the entire sale price for Primedica. The plaintiffs' complaint claims damages in the amount of $5 million. GTC has filed an
answer denying all the material allegations of the complaint and intends to vigorously defend the suit. 

Tax ID Number: 04-3186494 

Organizational Number, if any: Not applicable. 

29

  

As of Wednesday, March 27, 2002  

 
 

List of Granted Patents    
    
        (Attachment to Schedule to Loan and Security Agreement)    
    

	Case Number/Subcase

Case Type
 
	 	 
	 	Country

Division
	 	Patent Number

Issue Date
	 	Status

Expiration Date
	 	Attorney(s)
	 	Inventor(s)

	GTC-1/ORD	 	

 Title:	 	Australia

Genzyme Transgenics Corporation

Transgenic Production of Antibodies

in Milk	 	688,845

02-Jul-1998	 	Granted

20-Dec-2014	 	LBL

LM	 	Meade, Harry

Pollock, Daniel

DiTullio, Paul
	

GTC-1/ORD	
 	

 Title:	
 	

New Zealand

Genzyme Transgenics Corporation

Transgenic Production of Antibodies

in Milk	
 	

278744

18-Sep-1997	
 	

Granted

16-May-2016	
 	

LBL

LM	
 	

Meade, Harry

Pollock, Daniel

DiTullio, Paul
	

GTC-1/PRI	
 	

 Title:	
 	

United States of America

Genzyme Transgenics Corporation

Transgenic Production of Antibodies

in Milk	
 	

5,827,690

27-Oct-1998	
 	

Granted

27-Oct-2015	
 	

LBL

LM	
 	

Meade, Harry

Pollock, Daniel

DiTullio, Paul
	

GTC-1/D DIV	
 	

 Title:	
 	

United States of America

Genzyme Transgenics Corporation

Transgenic Production of Antibodies

in Milk	
 	

5,849,992

15-Dec-1998	
 	

Granted

15-Dec-2015	
 	

LBL

LM	
 	

Meade, Harry

Pollock, Daniel

DiTullio, Paul
	

GTC-10/PCT	
 	

 Title:	
 	

Australia

Genzyme Transgenics Corporation

Transgenically Produced

Antithrombin III	
 	

695249

26-Nov-1998	
 	

Granted

21-Feb-2016	
 	

LBL

LM	
 	

DiTullio, Paul

Meade, Harry

Cole, Edward S.
	

GTC-10/PRI	
 	

 Title:	
 	

United States of America

Genzyme Transgenics Corporation

Transgenically Produced

Antithrombin III	
 	

5,843,705

01-Dec-1998	
 	

Granted

01-Dec-2015	
 	

LBL

LM	
 	

DiTullio, Paul

Meade, Harry

Cole, Edward S.
	

GTC-13/PCT	
 	

 Title:	
 	

Australia

Genzyme Transgenics Corporation

Purification of Biologically Active Peptides from Milk	
 	

725993

08-Feb-2001	
 	

Granted

13-May-2017	
 	

LBL

LM	
 	

Kutzko, Joseph P

Hayes, Micheal L

Sherman, Lee T
	

GTC-13/PCT	
 	

 Title:	
 	

New Zealand

Genzyme Transgenics Corporation

Purification of Biologically Active Peptides from Milk	
 	

332916

07-Sep-2000	
 	

Granted

13-May-2017	
 	

LBL

LM	
 	

Kutzko, Joseph P

Hayes, Micheal L

Sherman, Lee T
	

GTC-13/PRI	
 	

 Title:	
 	

United States of America

Genzyme Transgenics Corporation

Purification of Biologically Active Peptides from Milk	
 	

6,268,487

31-Jul-2001	
 	

Granted

13-May-2016	
 	

LBL

LM	
 	

Kutzko, Joseph P

Hayes, Micheal L

Sherman, Lee T
	

GTC-14/ORD	
 	

 Title:	
 	

United States of America

Genzyme Transgenics Corporation

Transgenically Produced Prolactin	
 	

6,210,736

03-Apr-2001	
 	

Granted

15-Jun-2018	
 	

LBL

LM	
 	

Echelard, Yann

Wilburn, Brian
	

GTC-40/PCT	
 	

 Title:	
 	

African Union Territories (OAPI)

Genzyme Transgenics Corporation

Novel Modified Nucleic Acid Sequences and Methods for Increasing MRNA Levels and Protein Expression in

Cell Systems	
 	

11372

17-Oct-2000	
 	

Granted

20-Oct-2018	
 	

LBL

LM	
 	

Chen, Li-How

Meade, Harry
	

GTC-52/EPC	
 	

 Title:	
 	

Austria

Genzyme Transgenics Corporation

Process for Sterile Filtration of Milk	
 	

164489

01-Apr-1998	
 	

Granted

28-Jul-2014	
 	

 	
 	

 
	
 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 	
 	

 

30

 

	

GTC-52/EPC	
 	

 Title:	
 	

France

Genzyme Transgenics Corporation

Process for Sterile Filtration of Milk	
 	

638242

01-Apr-1998	
 	

Granted

28-Jul-2014	
 	

 	
 	

 
	

GTC-52/EPC	
 	

 Title:	
 	

Germany, Federal Republic of

Genzyme Transgenics Corporation

Process for Sterile Filtration of Milk	
 	

59405566

01-Apr-1998	
 	

Granted

28-Jul-2014	
 	

 	
 	

 
	

GTC-52/EPC	
 	

 Title:	
 	

Italy

Genzyme Transgenics Corporation

Process for Sterile Filtration of Milk	
 	

638242

01-Apr-1998	
 	

Granted

28-Jul-2014	
 	

 	
 	

 
	

GTC-52/EPC	
 	

 Title:	
 	

Switzerland

Genzyme Transgenics Corporation

Process for Sterile Filtration of Milk	
 	

638242

01-Apr-1998	
 	

Granted

28-Jul-2014	
 	

 	
 	

 
	

GTC-52/EPC	
 	

 Title:	
 	

United Kingdom

Genzyme Transgenics Corporation

Process for Sterile Filtration of Milk	
 	

638242

01-Apr-1998	
 	

Granted

28-Jul-2014	
 	

 	
 	

 
	

GTC-52/ORD	
 	

 Title:	
 	

United States of America

Genzyme Transgenics Corporation

Process for Sterile Filtration of Milk	
 	

5,576,040

19-Nov-1996	
 	

Granted

29-Jul-2014	
 	

 	
 	

 

31

  

 
 

Pending Patent Applications (US and Foreign)
  (Attachment to Schedule to Loan and Security Agreement)    
  

[*****]  

	*
	Confidential
Treatment has been requested for marked portion. 

32

  

 
 

List of Registered Trademarks
  (Attachment to Schedule to Loan and Security Agreement)    
  

	
 
	
 	

 
	
 	

 
	
 	

 

	General Matter	 	 	 	Wednesday, March 27, 2002
	
Case Number: GTC/TM-1	
 	
Status: Pending	
 	
Country(ies):	
 	

Attorney(s):
	

Title: ATRYN	
 	

 	
 	

European Community	
 	

 
	
Matter Type: Trademark	
 	

 	
 	

United States of America	
 	

 
	
Division: ATIII, LLC	
 	

 	
 	

 	
 	

 
	
Effective/Open Date:	
 	

Termination/End Date:

	
Remarks:	
 	

Application No. 76/184,729 filed in US 12/20/00

for Blood Plasma Protein

Class 5

filed in European Union 6/15/01—to include Austria, Belgium, Germany, Denmark, Spain, Finland, France, United Kingdom, Greece, Ireland, Italy, Luxembourg, Netherlands, Portugal and Sweden

Classes 5, 10, 42

F&R Ref. 10275-157001

User ID:
  Kristin 

Date Created:
  21-Jan-2002 

Last Update: 07-Feb-2002 

33

  

 
 

Schedule B
  
    GENZYME TRANSGENICS CORPORATION AND SUBSIDIARIES
  FIXED INCOME INVESTMENT POLICY    

APPLICABILITY  

        This Fixed Income Investment Policy applies to all cash investments made by or on behalf of Genzyme Transgenics Corporation ("GTC") and its subsidiaries. The
provisions of this policy apply whether the portfolio is managed internally or through one or more investment managers. 

OBJECTIVES OF THIS POLICY  

        This policy defines the investment objectives for the Fixed Income Portfolio, identifies investment guidelines (in terms of approved instruments, quality,
diversification, duration and liquidity) and establishes control and approval mechanisms for management of the portfolio. 

INVESTMENT OBJECTIVES  

        The investment objective of the portfolio is to provide GTC with an above market return consistent with the primary requirements of capital preservation and the
maintenance of appropriate liquidity. 

        The
GTC Treasury Department or the Company's Investment Manager(s), as appropriate, will construct and manage a diversified portfolio intended to meet that objective, consistent with the
specific Investment Guidelines included in this Fixed Income Investment Policy. It is recognized that securities purchased for GTC's portfolio may not earn as high a level of current income as
longer-term or lower quality securities which generally have less liquidity, greater market risk and more fluctuation in market value. 

INVESTMENT GUIDELINES  

1.    A.    Prohibited Investments  

        Under this policy, GTC is specifically prohibited from investing any portion of the GTC Fixed Income Investment Portfolio in the common equity of any company.
However, strategic equity investments made in accordance with specific authorization by GTC's Board of Directors or its designee shall be managed as part of the GTC Fixed Income Investment Portfolio. 

        No
portion of the GTC Fixed Income Investment Portfolio shall be invested in the following investment security types: convertible debt; reverse repurchase agreements; repurchase
agreements not backed by government or agency securities; long-term bond/fixed income funds or non-US dollar denominated securities. Futures contracts and options shall be used
for bona fide hedging transactions or risk management purposes only and are not approved solely for investment purposes under this policy. 

  B.    Approved Instruments  

        The following fixed income instruments are considered appropriate for the GTC Fixed Income Investment Portfolio: 

	a.
	Obligations
of the U.S. government or its agencies;

	b.
	Municipal
bonds, including pre-refunded bonds;

	c.
	Bank
obligations including banker's acceptances, notes, certificates of deposit and time deposits; 

34

 

	d.
	Corporate
notes and bonds, including commercial paper, repurchase agreements;

	e.
	U.S.
dollar denominated issues of foreign corporations or governments;

	f.
	Floating
rate securities, including variable rate demand notes;

	g.
	Asset-backed
securities (but only including securities backed by credit cards, auto receivables, or mortgages);

	h.
	Preferred
stock, but only including floating rate, Dutch auction and UK preferreds without interest rate caps provided that the availability of principal is consistent with approved
liquidity provisions and the "term" or "reset period" is consistent with approved maturity provisions;

	i.
	Debt
securities with Put or Call features;

	j.
	Money
market funds (consisting of fixed income assets only). 

2.    Quality  

        Individual holdings of commercial paper must, at the time of purchase, have a rating of at least A-1
from Standard and Poor's Corporation ("S&P") or P-1 from Moody's Investor Services ("Moody's"). 

        Securities
of issuers with a long-term credit rating or individual issues with long-term ratings must be rated at least A (S&P or Moody's
equivalent),except that Asset-backed securities must be rated AAA (S&P or Moody's equivalent). If an
investment falls into multiple categories the most stringent credit quality limit applies.

        If
a security held in the portfolio is downgraded by S&P or Moody's below the minimum rating specified above, the Investment Manager will notify the Chief Financial Officer and recommend
appropriate action. Written approval of the Chief Financial Officer is required to continue to hold any material investment which fails to meet minimum quality requirements. 

3.    Diversification (Note: the calculation of limitation is based on the market value (valued at the time of purchase) of the Fixed Income
Investment Portfolio. 

        Securities
of a single issuer, valued at the time of purchase, should not exceed 10% of the market value of the portfolio or $1 million, whichever is greater. 

4.    Marketability/Liquidity  

        This Fixed Income Investment Portfolio shall be structured so that securities mature as needed to meet the reasonably anticipated liquidity demands of GTC. GTC's
Treasury Department will monitor those needs and adjust the portfolio holdings accordingly. The portfolio shall consist only of securities that regularly trade in a secondary market under normal
conditions. 

5.    Maturity/Portfolio Duration  

        The duration of the Fixed Income Investment Portfolio shall average no more than 24 months. In addition, the final maturity of each security within the
portfolio shall not exceed three years. Except that, in the case of securities with regularly scheduled repayments, put dates or reset dates (i.e.,
Asset-backed securities or callable securities), the average expected maturity of all such securities may not exceed three years. 

35

 

6.    Gains and Losses  

        Trading activity in the GTC Fixed Income Investment Portfolio shall be consistent with market conditions, cash availability and liquidity requirements. The impact
of potential trading gains and/or losses on GTC's reported financial results can be significant. The Chief Financial Officer periodically shall establish maximum levels for such potential gains and/or
losses in any particular time period beyond which the prior written approval of the Chief Financial Officer is required. We intend to classify these securities as available for sale in accordance with
FAS115. 

7.    Tax Status of Investments  

        Securities purchased for the portfolio may be taxable, tax-exempt or tax advantaged except that, the
Director of Financial Reporting, in conjunction with the outside public accountants, will monitor issues that impact the desired tax status of the Fixed Income Investment Portfolio, and periodically
will recommend to the Chief Financial Officer changes in the tax status of portfolio holdings and investments. 

APPROVALS AND CONTROLS  

        All material changes to this policy require Board approval. The Chief Financial Officer is authorized to approve non-material changes to the policy. 

        The
Chief Financial Officer may adopt, at his discretion, Investment Guidelines and procedures that are more restrictive than those contained in this policy. 

        The
Chief Financial Officer may, with the approval of the Chief Executive Officer, appoint one or more third party professional investment managers to perform investment management
services related to the Fixed Income Investment Portfolio. The terms of any such appointment will be contained in a written contract between the parties. Together with provisions typical of such
contracts, the agreement will require adherence to the provisions of this Fixed Income Investment Policy and will contain such control, benchmarking and reporting requirements as are deemed to be
appropriate under the circumstances. 

        The
Investment Manager will report to the Chief Financial Officer on a quarterly basis on the performance of the Fixed Income Investment Portfolio. This report will include a review of
compliance with this Fixed Income Investment Policy. The Chief Financial Officer will report at least quarterly to the Board of Directors on these matters. 

Approved: GENZYME TRANSGENICS CORPORATION  

 Signature: /s/ John B. Green

John B. Green

Vice President and Chief Financial Officer          Date: March 1, 2000 

36

QuickLinks

LOAN AND SECURITY AGREEMENT

EXHIBIT A

EHIBIT B

EXHIBIT C COMPLIANCE CERTIFICATE

Schedule to Loan and Security Agreement

Schedule to Loan and Security Agreement

List of Granted Patents (Attachment to Schedule to Loan and Security Agreement)

Pending Patent Applications (US and Foreign) (Attachment to Schedule to Loan and Security Agreement)

List of Registered Trademarks (Attachment to Schedule to Loan and Security Agreement)

Schedule B GENZYME TRANSGENICS CORPORATION AND SUBSIDIARIES FIXED INCOME INVESTMENT POLICYQuickLinks
 -- Click here to rapidly navigate through this document
  

Exhibit 10.2  

 
 

PLEDGE AGREEMENT    
  

        PLEDGE AGREEMENT (this "Agreement"), dated as of March 27, 2002, by GENZYME TRANSGENICS CORPORATION, a
Massachusetts corporation ("Company"), a Massachusetts corporation, to SILICON VALLEY BANK, a California-chartered bank, with its principal place of
business at 3003 Tasman Drive, Santa Clara, California 95054 and with a loan production office located at One Newton Executive Park, 2221 Washington Street, Suite 200, Newton, Massachusetts 02462,
doing business under the name "Silicon Valley East" (the "Secured Party"). 

 
 

W I T N E S S E T H:    
  

        WHEREAS, Secured Party proposes to make certain loans to Company pursuant to a Loan and Security Agreement of even date herewith (the "Loan Agreement"). Any
capitalized terms used without definition herein shall have the meanings assigned to them in the Loan Agreement. 

        WHEREAS,
to induce the Secured Party to enter into the Loan Agreement and make the Loans thereunder, the Company has agreed to enter into this Pledge Agreement and pledge all of the
capital stock of the subsidiary listed on Schedule 1 (the "Subsidiary"), to the Secured Party; 

        NOW,
THEREFORE, in consideration of the foregoing and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Company and the Secured
Party hereby agree as follows: 

        SECTION
1.    Pledge.    The Company hereby grants, assigns and pledges to the Secured Party a valid lien on and
security interest in, all of the Company's right, title and interest in and to the following, whether now owned or at any time hereafter acquired (collectively, the "Collateral"): 

                (a)  All
of the issued and outstanding capital stock of the Company in the domestic Subsidiary as set forth on  Schedule 1 (the "Pledged Shares") and the certificates representing the Pledged Shares, and all
dividends, distributions, cash, instruments,
investment property and other property from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all of the Pledged Shares, and all additional capital
stock in Subsidiary from time to time acquired in any manner by the Company, and the certificates representing such additional capital stock, and all dividends, distributions, cash, instruments,
investment property and other property from time to time received, receivable or otherwise distributed in respect of or in exchange for any or all of such capital stock; and 

                (b)  all
proceeds of any of the foregoing (including, without limitation, proceeds constituting any property of the types described above). 

        SECTION
2.    All Obligations Secured.    This Agreement secures the prompt and complete payment and performance when
due (whether at the stated maturity, by acceleration or otherwise) of all of the Obligations. 

        SECTION
3.    Representations and Warranties.    Company represents and warrants as follows: 

                (a)  Company
has the requisite corporate power and authority to execute, deliver and perform this Agreement and all corporate action necessary for the execution, delivery
and performance of this Agreement has been taken. 

                (b)  The
execution, delivery and performance of this Agreement by Company does not, and will not, contravene (i) the Certificate of Incorporation and
By-Laws of Company, (ii) any legal requirement or (iii) any material franchise, license, permit, indenture, contract, lease, agreement, instrument or other commitment to
which it is a party or by which it or any of its properties are bound, 

1

 

and will not, except as contemplated herein, result in the imposition of any liens or security interests upon any of its properties. 

                (c)  This
Agreement is the legal, valid and binding obligation of Company, enforceable in accordance with its terms. 

                (d)  Company
is the legal and beneficial owner of record of the Pledged Shares set forth opposite Company's name in  Schedule 1, free and clear of any lien other than liens created pursuant to this Agreement. On
the date hereof, no effective financing statement
or other instrument similar in effect covering all or any part of the Collateral will be on file in any recording office. 

                (e)  The
pledge of the Collateral and granting of the liens hereunder, together with the delivery of the stock certificates pledged hereunder and appropriate filings of
Uniform Commercial Code financing statements, create a valid and perfected first priority lien on the Collateral, securing the payment and performance of the Obligations, and all filings and other
actions necessary or desirable to perfect and protect such lien have been duly made or taken. 

                (f)    No
authorization, approval, or other action by, and no notice to or filing with, any Person or governmental authority is required for (i) the pledge by such
Company of the Collateral pursuant to this Agreement, the grant by such Company of the liens granted hereby or the execution, delivery or performance of this Agreement by such Company, (ii) the
perfection of the liens granted pursuant to this Agreement, except for the delivery to the Secured Party of the stock certificates representing the Pledged Shares in Subsidiary and appropriate filings
of Uniform Commercial Code financing statements, or (iii) the exercise by the Secured Party of the rights or remedies provided for in this Agreement. 

                (g)  The
Pledged Shares represented by the certificates identified in Schedule 1 are, and all other Pledged Shares in
which Company shall hereafter obtain an interest will be duly authorized, fully paid and nonassessable and none of such Pledged Shares is or will be subject to any contractual restriction upon the
transfer of such Pledged Shares. 

                (h)  The
Pledged Shares represented by the certificates identified in Schedule 1 constitute all of the issued and
outstanding shares of capital stock or other equity securities of any class in the Subsidiary, and Schedule 1 correctly identifies, as at the
date hereof, the respective class of the shares comprising such Pledged Shares and the respective number of shares represented by each such certificate. 

        SECTION
4.    Further Assurances; Covenants; Replacement Collateral.    

                (a)  Company
covenants and agrees that at any time and from time to time, at the expense of Company, Company will promptly execute and deliver all further instruments and
documents, and take all further action, that may be necessary or desirable, or that the Secured Party may reasonably request, to perfect and protect any security interest granted or purported to be
granted hereby or to enable the Secured Party to exercise and enforce its rights and remedies hereunder with respect to any Collateral. Without limiting the generality of the foregoing, Company will
execute and file such financing or continuation statements, or amendments thereto, and such other instruments or notices, as may be necessary or desirable, or as the Secured Party may reasonably
request, to perfect and preserve the liens granted or purported to be granted hereby, and cause third parties to acknowledge and to register the pledge of
securities hereunder on their books and to deliver statements of account upon the Secured Party's request therefor. 

                (b)  Company
covenants and agrees that, without the prior written consent of the Secured Party, Company will not (i) sell, assign (by operation of law or otherwise)
or otherwise dispose of, or grant any option with respect to, any of the Collateral, (ii) create or suffer to exist any lien upon or with respect to any of the Collateral, except for the liens
under this Agreement, (iii) vote to enable, or 

2

 

take any other action to permit, Subsidiary to issue any capital stock or other equity securities of any nature or to issue any other securities convertible into, exchangeable for or granting the
right to purchase any capital stock or other equity securities of any nature of Subsidiary or to convey, exchange, lease, assign, transfer, sell or otherwise dispose of any material assets of the
Subsidiary (except that Genzyme Transgenics Securities Corporation may make dividends to the Company), (iv) enter into any agreement or undertaking restricting the right or ability of the
Secured Party to sell, assign or transfer any of the Collateral or (v) permit Subsidiary to issue any shares of capital stock or other equity securities of any nature or to issue any securities
convertible into or granting the right to purchase or otherwise acquire any shares of capital stock or equity securities of Subsidiary or to convey, exchange, lease, assign, transfer, sell or
otherwise dispose of any material assets of the Subsidiary. 

                (c)  If
Company creates any new subsidiary or acquires any additional capital stock in any Subsidiary, Company shall hold the same in trust for the Secured Party and
promptly deliver to the Secured Party the stock certificates evidencing such capital stock, together with undated stock powers related thereto duly executed in blank by Company. 

        SECTION
5.    Rights of the Company; Voting; etc.    

                (a)  So
long as no Event of Default shall have occurred and be continuing, Company shall be entitled to exercise any and all voting and other consensual rights pertaining to
the Collateral or any part thereof for any purpose not inconsistent with the terms of this Agreement and the other Loan Documents and in a manner which does not impair any of the Collateral and to
receive and retain any and all cash dividends and distributions paid in respect of the Pledged Shares. 

                (b)  Upon
the occurrence and during the continuance of an Event of Default: 

                        (i)    All
rights of any Company to receive the cash dividends and distributions that such Company would otherwise be authorized to receive and retain pursuant to
Section 5(a) hereof shall cease, and all such rights shall thereupon become vested in the Secured Party who shall thereupon have the sole right to receive and hold as Collateral such dividends,
distributions and payments. 

                        (ii)  Any
and all other dividends and distributions payable to any Company in respect of the Collateral shall be received by such Company in trust for the benefit of the
Secured Party, shall be segregated from other funds of such Company and shall be forthwith paid over to the Secured Party as Collateral in the same form as so received (with any necessary
endorsement). 

        SECTION
6.    Principal Place of Business; Records.    Company shall keep its principal place of business and the
place where it keeps its records concerning the Collateral at the address of the Company specified in the Loan Agreement. The Company will hold and preserve such records and, upon reasonable notice
from the Secured Party, will permit representatives of the Secured Party at any time during normal business hours to inspect and make abstracts from such records. 

        SECTION
7.    Transfer or Liens.    Company agrees that it will not sell, transfer or convey any interest in, grant
any option with respect to, or suffer or permit any lien to be created upon or with respect to, any of the Pledged Shares during the term of this Agreement, except to or in favor of the Secured Party. 

        SECTION
8.    Secured Party Appointed Attorney-in-Fact; Irrevocable Authorization and Instruction to the
Subsidiary.    Company hereby appoints the Secured Party as Company's attorney-in-fact, with full authority in the place and stead of the
Company and in the name of the Company or otherwise, from time to time in the Secured Party's discretion, to, upon the occurrence and during the continuance of an Event of Default, take any action and
to execute any instrument which the Secured Party may deem necessary or advisable to accomplish the purposes of this Agreement, including, without limitation, to exercise the voting and other
consensual rights which Company would otherwise be entitled to exercise pursuant to Section 5(a) (and all right of Company to exercise such rights shall cease) and to receive, 

3

 

endorse and collect all instruments made payable to the Company representing any distribution in respect of the Collateral or any part thereof and to give full discharge for the same. Company hereby
authorizes and instructs Subsidiary to comply with any instruction received by it from the Secured Party in writing that (i) states that an Event of Default has occurred and is continuing and
(ii) is otherwise in accordance with the terms of this Agreement, without any other or further instructions from Company, and Company agrees that Subsidiary shall be fully protected in so
complying. Company hereby ratifies all that such attorney shall lawfully do or cause to be done by virtue hereof. This power of attorney is coupled with an interest and is irrevocable. 

        SECTION
9.    Reasonable Care; Return of Collateral.    

                (a)  Prior
to the exercise of its remedies hereunder, the Secured Party shall be deemed to have exercised reasonable care in the custody and preservation of the Collateral
in its possession if the Collateral is accorded treatment substantially equal to that which the Secured Party accords its own similar property, it being understood that the Secured Party shall not
have the responsibility under this Agreement for taking any necessary steps to preserve rights against any parties with respect to any Collateral except as set forth in subsection (b) below. 

                (b)  Upon
the indefeasible payment in full in cash of all the Obligations and the termination of the Loan Agreement, Company shall be entitled to the return of all of the
Collateral pledged by Company hereunder. 

        SECTION
10.    Secured Party May Perform.    If Company fails to perform any agreement contained herein, the Secured
Party may itself perform, or cause performance of, such agreement, and the expenses of the Secured Party incurred in connection therewith shall be payable by such Company. 

        SECTION
11.    Remedies upon Default.    If any Event of Default shall have occurred and be continuing, the Secured
Party may exercise in respect of the Collateral, in addition to other rights and remedies provided for herein or otherwise available to it, all the rights and remedies of a secured party under the
Uniform Commercial Code (the "Code") and the Secured Party may also, without notice except as specified below, transfer the Collateral into its name or that of its nominee, sell the Collateral or any
part thereof in one or more parcels at public or private sale, at any exchange, broker's board or at any of the Secured Party's offices or elsewhere, for cash, on credit or for future delivery, and
upon such other terms as the Secured Party may deem commercially reasonable. Company agrees that, to the extent notice of sale shall be required by law, at least ten (10) days' notice to
Company of the time and place of any public sale or the time after which any private sale is to be made shall constitute reasonable notification. The Secured Party shall not be obligated to make any
sale of Collateral regardless of notice of sale having been given. The Secured Party may adjourn any public or private sale from time to time by announcement at the time and place fixed therefor, and
such sale may, without further notice, be made at the time and place to which it was so adjourned. 

        SECTION
12.    Indemnity and Expenses.    

                (a)  Company
agrees to and hereby indemnifies the Secured Party, from and against any and all claims, damages, losses, liabilities and expenses arising out of, or in
connection with, or resulting from, this Agreement (including, without limitation, enforcement of this Agreement) other than such as arise from the Secured Party's gross negligence or willful
misconduct. 

                (b)  Company
will, upon demand, pay to the Secured Party the amount of any and all expenses, including the reasonable fees and expenses of its counsel and of any experts and
agents, that the Secured Party may incur in connection with (i) the administration of this Agreement, (ii) the custody or preservation of, or the sale of, collection from, or other
realization upon, any of the Collateral, (iii) the exercise or enforcement of any of the rights of the Secured Party hereunder, (iv) the failure of Company to perform or observe any of
the provisions hereof, or (v) any action taken by the Secured Party pursuant to this Agreement. 

4

 

        SECTION
13.    Security Interest Absolute.    All rights of the Secured Party and security interests hereunder, and
all obligations of Company hereunder, shall be absolute and unconditional irrespective of: 

                (a)  any
lack of validity or enforceability of the Loan Agreement, or any other Loan Document; 

                (b)  any
change in the time, manner or place of payment of, or in any other term of, all or any of the Obligations, or any other amendment or waiver of or any consent to
departure from any of the Loan Documents; 

                (c)  any
taking and holding of collateral or any guaranty for all or any of the Obligations, or any amendment, alteration, exchange, substitution, transfer, enforcement,
waiver, subordination, termination or release of any collateral or such guaranty, or any non-perfection of any collateral, or any consent to departure from any such guaranty; 

                (d)  any
manner of application of collateral, or proceeds thereof, to all or any of the Obligations, or the manner of sale of any collateral; 

                (e)  any
consent by Secured Party to the restructure of the Obligations, or any other restructure or refinancing of the Obligations or any portion thereof; 

                (f)    any
modification, compromise, settlement or release by the Secured Party, by operation of law or otherwise, collection or other liquidation of the Obligations or the
liability of any guarantor, or of any collateral, in whole or in part, and any refusal of payment by the Secured Party, in whole or in part, from any obligor or guarantor in connection with any of the
Obligations, whether or not with notice to, or further assent by, or any reservation of rights against, any Company; or 

                (g)  any
other circumstance (including, without limitation, any statute of limitations) which might otherwise constitute a defense available to, or a discharge of, any third
party pledgor or guarantor. 

        SECTION
14.    Amendments; Waivers; Partial Exercise.    No amendment or waiver of any provision of this Agreement or
consent to any departure by the Company here from shall be effective unless in writing and signed by Company and the Secured Party and any such amendment, waiver or consent shall be effective only to
the extent set forth therein. No failure to exercise or any delay in exercising on the part of the Secured Party any right, power or privilege under this Agreement shall operate as a waiver thereof.
No single or partial exercise of any right, power or privilege under this Agreement shall preclude any other or further exercise thereof or the exercise of any other right, power or privilege. 

        SECTION
15.    Addresses for Notices.    All notices and correspondence hereunder shall be provided in the manner, to
the Persons and to the addresses set forth in the Loan Agreement. 

        SECTION
16.    Continuing Security Interest; Assignments of Secured Debt.    This Agreement shall create a continuing
security interest in and lien on the Collateral and shall (i) remain in full force and effect until released in accordance with the terms hereof, (ii) be binding upon Company, its
successors and assigns, and (iii) inure, together with the rights and remedies of the Secured Party hereunder, to the benefit of its respective successors and assigns. Without limiting the
generality of the foregoing clause (iii), the Secured Party, in accordance with the terms of the Loan Agreement, may assign or otherwise transfer all or any portion of their rights and
obligations under this Agreement to any other Person, and such other Person shall thereupon become vested with all the benefits in respect hereof granted herein. 

        SECTION
17.    Governing Law; Defined Terms.    This Agreement shall be governed by and construed in accordance with
the laws of the Commonwealth of Massachusetts without giving effect to principles of conflicts of law. Unless otherwise defined herein or in the Loan Agreement, terms used in 

5

 

Articles 8 and 9 of the Code are used herein as therein defined. This Agreement shall be deemed for all purposes to be a Loan Document under the Loan Agreement. 

        SECTION
18.    Marshalling.    Company hereby waives any right to require the Secured Party to marshal any security or
Collateral or otherwise compel the Secured Party seek recourse against or satisfaction of the Obligations from one source before seeking recourse or satisfaction from another source. 

        SECTION
19.    Execution in Counterparts; Telecopied Signatures.    This Agreement may be executed in counterparts,
each of which shall constitute an original, but all of which taken together shall constitute one and the same instrument. This Agreement, and any notices to be given pursuant to this Agreement, may be
executed and delivered by telecopier or other facsimile transmission all with the same force and effect as if the same was a fully executed and delivered original counterpart. 

        SECTION
20.    SUBMISSION TO JURISDICTION.    COMPANY AGREES THAT ANY SUIT FOR THE ENFORCEMENT OF THIS AGREEMENT OR
ANY OF THE OTHER LOAN DOCUMENTS MAY BE BROUGHT IN THE COURTS OF THE COMMONWEALTH OF MASSACHUSETTS OR ANY FEDERAL COURT SITTING THEREIN AND CONSENTS TO THE NONEXCLUSIVE JURISDICTION OF SUCH COURT AND
SERVICE OF PROCESS IN ANY SUCH SUIT BEING MADE UPON COMPANY BY MAIL AT THE ADDRESS SET FORTH ABOVE. COMPANY HEREBY WAIVES ANY OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE VENUE OF ANY SUCH SUIT
OR ANY SUCH COURT OR THAT SUCH SUIT IS BROUGHT IN AN INCONVENIENT FORUM. 

        SECTION
21.    JURY TRIAL.    COMPANY AND SECURED PARTY (BY ACCEPTANCE OF THIS AGREEMENT) MUTUALLY HEREBY KNOWINGLY,
VOLUNTARILY AND INTENTIONALLY WAIVE THE RIGHT TO A TRIAL BY JURY IN RESPECT OF ANY CLAIM BASED HEREON, ARISING OUT OF, UNDER OR IN CONNECTION WITH THIS AGREEMENT OR ANY OTHER LOAN DOCUMENTS
CONTEMPLATED TO BE EXECUTED IN CONNECTION HEREWITH OR ANY COURSE OF CONDUCT, COURSE OF DEALINGS, STATEMENTS (WHETHER VERBAL OR WRITTEN) OR ACTIONS OF ANY PARTY, INCLUDING, WITHOUT LIMITATION, ANY
COURSE OF CONDUCT, COURSE OF DEALINGS, STATEMENTS OR ACTIONS OF SECURED PARTY RELATING TO THE ADMINISTRATION OF THE LOANS OR ENFORCEMENT OF THE LOAN DOCUMENTS, AND AGREE THAT NEITHER PARTY WILL SEEK
TO CONSOLIDATE ANY SUCH ACTION WITH ANY OTHER ACTION IN WHICH A JURY TRIAL CANNOT BE OR HAS NOT BEEN WAIVED. EXCEPT AS PROHIBITED BY LAW, COMPANY HEREBY WAIVES ANY RIGHT IT MAY HAVE TO CLAIM OR
RECOVER IN ANY LITIGATION ANY SPECIAL, EXEMPLARY, PUNITIVE OR CONSEQUENTIAL DAMAGES OR ANY DAMAGES OTHER THAN, OR IN ADDITION TO, ACTUAL DAMAGES. COMPANY CERTIFIES THAT NO REPRESENTATIVE, AGENT OR
ATTORNEY OF SECURED PARTY HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SECURED PARTY WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER. THIS WAIVER CONSTITUTES A MATERIAL
INDUCEMENT FOR SECURED PARTY TO ACCEPT THIS AGREEMENT AND MAKE THE LOANS. 

        SECTION
22.    Lost Items.    Upon receipt of an affidavit of an officer of Secured Party as to the loss, theft,
destruction or mutilation of this Agreement or any certificates delivered in connection therewith which is not of public record, and, in the case of any such loss, theft, destruction or mutilation,
upon cancellation of such Agreement or certificate, the Company will issue, or cause to be issued, in lieu thereof, a replacement. 

6

 

        IN
WITNESS WHEREOF, the Company has caused this Agreement to be executed by its proper and duly authorized officer as of the day and year first above written. 

	 	 	GENZYME TRANSGENICS CORPORATION
	

 	
 	

By:	
 	

/s/  JOHN B. GREEN      
 Name: John B. Green

Title: Senior Vice President

Accepted:

	SILICON VALLEY BANK
	

By:	
 	

/s/  MICHAEL J. HAREWICK      
 Name: Michael J. Harewick

Title: Senior Vice President

7

 
 
 
 

Schedule 1
  
    Pledge Agreement between Genzyme Transgenics Corporation
  and Silicon Valley Bank, as Secured Party    
  

Pledged Shares  

Issuer:
Genzyme Transgenics Securities Corporation, a Massachusetts security corporation 

Class
of Shares: Common 

Number
of Pledged Shares: 100 

Date
of Issuance: December 3, 1993 

Date
of Pledge: March    , 2002 

8

QuickLinks

PLEDGE AGREEMENT

W I T N E S S E T H

Schedule 1

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00038-of-00352.parquet"}]]